melatonin has been researched along with Alzheimer Disease in 277 studies
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The current review aims to examine melatonin therapy for both sleep disturbances and cognitive function in dementia." | 8.91 | Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. ( Chen, SD; Dammer, EB; Li, CB; Wang, G; Wang, LL; Xu, G; Xu, J, 2015) |
| " In the present study, we aimed to examine the protective effect of melatonin against hyperglycemia-induced alterations in the amyloidogenic pathway." | 8.12 | Melatonin Attenuates High Glucose-Induced Changes in Beta Amyloid Precursor Protein Processing in Human Neuroblastoma Cells. ( Boontem, P; Chaopae, W; Govitrapong, P; Nopparat, C; Sopha, P; Wongchitrat, P, 2022) |
| "Initial evening secretion of melatonin proves to be delayed and mildly impaired in patients with a mild/moderate form of Alzheimer disease while patients' subjective sleep parameters and chronotype are reported to be similar to those of HC." | 7.91 | Evening melatonin timing secretion in real life conditions in patients with Alzheimer disease of mild to moderate severity. ( Cerri, S; Cremascoli, R; De Icco, R; Ghezzi, C; Manni, R; Perretti, C; Picascia, M; Sinforiani, E; Terzaghi, M, 2019) |
| " In this study, we examined the underlying neuroprotective mechanism of melatonin against D-galactose-induced memory and synaptic dysfunction, elevated reactive oxygen species (ROS), neuroinflammation and neurodegeneration." | 7.81 | Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF-K B/JNK signaling pathway in aging mouse model. ( Ali, T; Badshah, H; Kim, MO; Kim, TH, 2015) |
| "Aluminum (Al) is a known neurotoxic element involved in the etiology of some serious neurodegenerative disorders such as Alzheimer disease (AD)." | 7.80 | Chronic exposure to aluminum and melatonin through the diet: neurobehavioral effects in a transgenic mouse model of Alzheimer disease. ( Colomina, MT; Di Paolo, C; Domingo, JL; Gómez, M; Reverte, I, 2014) |
| "A disturbed sleep-wake rhythm is common in Alzheimer disease (AD) patients and correlated with decreased melatonin levels and a disrupted circadian melatonin rhythm." | 7.72 | Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. ( Feenstra, MG; Fischer, DF; Liu, RY; Ravid, R; Swaab, DF; Toranõ, JS; Van Kan, HJ; Wu, YH; Zhou, JN, 2003) |
| "Serum melatonin, Zn, Cu, Fe, and malondialdehyde (MDA) concentrations and erythrocyte superoxide dismutase (SOD) activity were measured in patients with Alzheimer disease." | 7.71 | Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. ( Delibas, N; Ozcankaya, R, 2002) |
| "The daily rhythm in serum melatonin levels was measured in patients with dementia of the degenerate type (Alzheimer's disease, Pick's disease and senile dementia of the Alzheimer type) by radioimmunoassay." | 7.69 | Daily rhythm of serum melatonin in patients with dementia of the degenerate type. ( Morita, Y; Ohara, K; Okamoto, N; Uchida, K, 1996) |
| " In this study we demonstrate that melatonin, a pineal hormone with recently established antioxidant properties, is remarkably effective in preventing death of cultured neuroblastoma cells as well as oxidative damage and intracellular Ca2+ increases induced by a cytotoxic fragment of Abeta." | 7.69 | Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. ( Bick, RJ; Efthimiopoulos, S; Hickson-Bick, DL; Omar, RA; Pappolla, MA; Reiter, RJ; Robakis, NK; Sos, M, 1997) |
| "In most countries, neurodegenerative diseases are generally recognized as the number one cause afflicting the elderly." | 7.01 | Melatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress. ( Joo, SS; Yoo, YM, 2023) |
| "Patients with Alzheimer dementia often display both agitated behavior and poor sleep." | 6.74 | Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. ( Ancoli-Israel, S; Connor, DJ; Corey-Bloom, J; Gehrman, PR; Martin, JL; Shochat, T, 2009) |
| "Brain disorders such as Alzheimer's and Parkinson's disease (PD) are irreversible conditions with several cognitive problems, including learning disabilities, memory loss, movement abnormalities, and speech problems." | 6.72 | Melatonin hormone as a therapeutic weapon against neurodegenerative diseases. ( Alghamdi, S; Almehmadi, M; Asefy, Z; Dablool, AS; Eftekhari, A; Hoseinnejhad, S; Kazemi, E; Khusro, A; Mammadova, S; Sahibzada, MUK, 2021) |
| "Neurodegenerative diseases are the second most common cause of death and characterized by progressive impairments in movement or mental functioning in the central or peripheral nervous system." | 6.66 | Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases. ( Chen, D; Lee, TH; Zhang, T, 2020) |
| "Melatonin is a neuroendocrine hormone mainly synthesized in the pineal gland and exhibits a wide range of biological functions, such as sleep control, regulating circadian rhythm, immune enhancement, metabolism regulation, antioxidant, anti-aging, and anti-tumor effects." | 6.66 | Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases. ( Akbar, M; Luo, F; Rungratanawanich, W; Sandhu, AF; Song, BJ; Wang, X; Williams, GE; Zhou, S, 2020) |
| "Melatonin not only plays an important role in the regulation of circadian rhythms, but also acts as antioxidant and neuroprotector that may be of importance in aging and Alzheimer's disease (AD)." | 6.43 | The human pineal gland and melatonin in aging and Alzheimer's disease. ( Swaab, DF; Wu, YH, 2005) |
| "Melatonin has been shown to be effective in arresting neurodegenerative phenomena seen in experimental models of Alzheimer's disease, Parkinsonism and ischemic stroke." | 6.43 | Role of melatonin in neurodegenerative diseases. ( Cardinali, DP; Esquifino, AI; Hardeland, R; Maestroni, GJ; Pandi-Perumal, SR; Srinivasan, V, 2005) |
| "Melatonin plays a protective role against Aβ-induced inflammation via an inflammasome-associated mechanism that is essential in inducing the active forms of cytokines and pyroptosis." | 5.91 | The role of melatonin in amyloid beta-induced inflammation mediated by inflammasome signaling in neuronal cell lines. ( Boontor, A; Govitrapong, P; Kutpruek, S; Nopparat, C, 2023) |
| "Pretreatment with melatonin significantly reversed METH-induced APP-cleaving secretases and Aβ production." | 5.72 | Melatonin Attenuates Methamphetamine-Induced Alteration of Amyloid β Precursor Protein Cleaving Enzyme Expressions via Melatonin Receptor in Human Neuroblastoma Cells. ( Boontor, A; Govitrapong, P; Nopparat, C; Panmanee, J, 2022) |
| "Rosacea is significantly associated with dementia, particularly Alzheimer's disease (AD)." | 5.62 | Bioinformatics and Network Pharmacology Identify the Therapeutic Role and Potential Mechanism of Melatonin in AD and Rosacea. ( Deng, Z; Li, J; Li, Y; Wang, Y; Xie, H; Xu, S; Yan, S; Yang, X; Zhang, H; Zhang, Y, 2021) |
| "Melatonin was effective in the memory facilitating effects only when administered in the afternoon." | 5.39 | A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease. ( He, P; Laudon, M; Ouyang, X; Tang, C; Tian, S; Yin, W; Zhou, S, 2013) |
| "Delirium is a common and serious acute neuropsychiatric syndrome characterized by inattention and global cognitive dysfunction." | 5.38 | Marked improvement in delirium with ramelteon: five case reports. ( Furuya, M; Horiguchi, J; Miyaoka, T; Otsuka, S; Tanaka, I; Wake, R; Yamashita, S; Yasuda, H, 2012) |
| " Chronic administration of melatonin (0." | 5.31 | Possible antioxidant mechanism in melatonin reversal of aging and chronic ethanol-induced amnesia in plus-maze and passive avoidance memory tasks. ( Kulkarni, SK; Raghavendra, V, 2001) |
| "Melatonin pre-treatment reversed the deleterious effects of cobalt." | 5.31 | Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion. ( Baysang, G; Brockhaus, M; Hess, C; Ly, C; Meier, F; Müller-Spahn, F; Olivieri, G; Savaskan, E, 2001) |
| "The current review aims to examine melatonin therapy for both sleep disturbances and cognitive function in dementia." | 4.91 | Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. ( Chen, SD; Dammer, EB; Li, CB; Wang, G; Wang, LL; Xu, G; Xu, J, 2015) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "This observation suggests that targeting of Notch1 signaling might be a promising therapeutic approach for AD and other age-associated neurodegenerative diseases, and melatonin might serve as a potential therapeutic agent for AD and other age-associated neurodegenerative diseases." | 4.31 | Regulatory role of melatonin in Notch1 signaling pathway in cerebral cortex of Aβ ( Bi, J; Hu, C; Ren, L; Wang, P; Zhang, S, 2023) |
| " In the present study, we aimed to examine the protective effect of melatonin against hyperglycemia-induced alterations in the amyloidogenic pathway." | 4.12 | Melatonin Attenuates High Glucose-Induced Changes in Beta Amyloid Precursor Protein Processing in Human Neuroblastoma Cells. ( Boontem, P; Chaopae, W; Govitrapong, P; Nopparat, C; Sopha, P; Wongchitrat, P, 2022) |
| "Initial evening secretion of melatonin proves to be delayed and mildly impaired in patients with a mild/moderate form of Alzheimer disease while patients' subjective sleep parameters and chronotype are reported to be similar to those of HC." | 3.91 | Evening melatonin timing secretion in real life conditions in patients with Alzheimer disease of mild to moderate severity. ( Cerri, S; Cremascoli, R; De Icco, R; Ghezzi, C; Manni, R; Perretti, C; Picascia, M; Sinforiani, E; Terzaghi, M, 2019) |
| " In this study, we examined the underlying neuroprotective mechanism of melatonin against D-galactose-induced memory and synaptic dysfunction, elevated reactive oxygen species (ROS), neuroinflammation and neurodegeneration." | 3.81 | Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF-K B/JNK signaling pathway in aging mouse model. ( Ali, T; Badshah, H; Kim, MO; Kim, TH, 2015) |
| "Aluminum (Al) is a known neurotoxic element involved in the etiology of some serious neurodegenerative disorders such as Alzheimer disease (AD)." | 3.80 | Chronic exposure to aluminum and melatonin through the diet: neurobehavioral effects in a transgenic mouse model of Alzheimer disease. ( Colomina, MT; Di Paolo, C; Domingo, JL; Gómez, M; Reverte, I, 2014) |
| " In APP-expressing neuroblastoma cells in culture, mitochondrial function was restored by melatonin or by the structurally related compounds indole-3-propionic acid or N(1)-acetyl-N(2)-formyl-5-methoxykynuramine." | 3.77 | Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. ( Arendash, GW; Bradshaw, PC; Buzzeo, R; Cao, C; Copes, N; Dragicevic, N; Jin, J; Mamcarz, M; O'Neal-Moffitt, G; Olcese, JM; Tan, J, 2011) |
| "A disturbed sleep-wake rhythm is common in Alzheimer disease (AD) patients and correlated with decreased melatonin levels and a disrupted circadian melatonin rhythm." | 3.72 | Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. ( Feenstra, MG; Fischer, DF; Liu, RY; Ravid, R; Swaab, DF; Toranõ, JS; Van Kan, HJ; Wu, YH; Zhou, JN, 2003) |
| "We generated a neuroblastoma (SH-SY5Y) cell system in which cytoskeletal proteins are abnormally phosphorylated resulting in microtubule disruption due to the marked inhibition of protein phosphatase activities by okadaic acid (OA)." | 3.72 | Melatonin ameliorated okadaic-acid induced Alzheimer-like lesions. ( Li, XT; Liu, SJ; Wang, JZ; Wang, XC; Wang, YP; Zhou, XW, 2004) |
| "Serum melatonin, Zn, Cu, Fe, and malondialdehyde (MDA) concentrations and erythrocyte superoxide dismutase (SOD) activity were measured in patients with Alzheimer disease." | 3.71 | Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. ( Delibas, N; Ozcankaya, R, 2002) |
| "The simultaneous evaluation of the circadian rhythm of plasma melatonin and ACTH and of serum cortisol and DHEAS represents a clinically reliable tool to appreciate the neuroendocrine changes occurring in physiological and pathological brain aging." | 3.70 | Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. ( Arcaini, A; Cravello, L; Ferrari, E; Fioravanti, M; Gornati, R; Magri, F; Pelanconi, L; Solerte, SB, 2000) |
| "The daily rhythm in serum melatonin levels was measured in patients with dementia of the degenerate type (Alzheimer's disease, Pick's disease and senile dementia of the Alzheimer type) by radioimmunoassay." | 3.69 | Daily rhythm of serum melatonin in patients with dementia of the degenerate type. ( Morita, Y; Ohara, K; Okamoto, N; Uchida, K, 1996) |
| " In this study we demonstrate that melatonin, a pineal hormone with recently established antioxidant properties, is remarkably effective in preventing death of cultured neuroblastoma cells as well as oxidative damage and intracellular Ca2+ increases induced by a cytotoxic fragment of Abeta." | 3.69 | Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. ( Bick, RJ; Efthimiopoulos, S; Hickson-Bick, DL; Omar, RA; Pappolla, MA; Reiter, RJ; Robakis, NK; Sos, M, 1997) |
| "In most countries, neurodegenerative diseases are generally recognized as the number one cause afflicting the elderly." | 3.01 | Melatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress. ( Joo, SS; Yoo, YM, 2023) |
| "Melatonin is a sleep-promoting agent, with waste clearance from the CNS being highest especially during slow wave sleep." | 3.01 | Brain washing and neural health: role of age, sleep, and the cerebrospinal fluid melatonin rhythm. ( Cucielo, MS; de Almeida Chuffa, LG; Gancitano, G; Reiter, RJ; Rosales-Corral, S; Sharma, R; Tan, DX, 2023) |
| "Melatonin is a potent antioxidant that lowers viscosity to increase ATP by scavenging excess reactive oxygen species and free radicals." | 3.01 | Light, Water, and Melatonin: The Synergistic Regulation of Phase Separation in Dementia. ( Loh, D; Reiter, RJ, 2023) |
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases worldwide." | 3.01 | Role of Bmal1 and Gut Microbiota in Alzheimer's Disease and Parkinson's Disease Pathophysiology: The Probable Effect of Melatonin on Their Association. ( Esmaeili, A; Ghasemnejad-Berenji, M; Khezri, MR, 2023) |
| "BACKGROUND Alzheimer's disease (AD) is a degenerative disease that is characterized by massive neuron devastations in the hippocampus and cortex." | 2.94 | Dietary Melatonin Therapy Alleviates the Lamina Cribrosa Damages in Patients with Mild Cognitive Impairments: A Double-Blinded, Randomized Controlled Study. ( Geng, Y; Hu, B; Sun, H; Xu, L; Yu, H, 2020) |
| " Switching to morning dosing or to an alternative drug may help." | 2.82 | [Sleep disorders in patients with a neurocognitive disorder]. ( Carrier, J; Dang-Vu, TT; Moderie, C, 2022) |
| "Diseases such as Alzheimer's, type 2 diabetes mellitus (T2DM), Parkinson's, atherosclerosis, hypertension, and osteoarthritis are age-related, and most of these diseases are comorbidities or risk factors for AD; however, our understandings of molecular events that regulate the occurrence of these diseases are still not fully understood." | 2.82 | Importance of Bmal1 in Alzheimer's disease and associated aging-related diseases: Mechanisms and interventions. ( Chen, J; Dong, K; Fan, R; Ma, D; Peng, X; Shi, X; Xie, L; Xu, W; Yang, Y; Yu, X; Zhang, S, 2022) |
| "Melatonin (MT) has been reported to control and prevent Alzheimer's disease (AD) in the clinic; however, the effect and mechanism of MT on AD have not been specifically described." | 2.82 | Effect and Mechanism of Exogenous Melatonin on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic Review and Meta-analysis. ( Qin, T; Sun, T; Xie, D; Xu, Y; Zhai, Z; Zhong, Y, 2022) |
| "A link between poor sleep quality and Alzheimer's disease (AD) has recently been suggested." | 2.79 | Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. ( Farmer, M; Frydman-Marom, A; Fund, N; Harari, G; Laudon, M; Nir, T; Wade, AG; Zisapel, N, 2014) |
| "Patients with Alzheimer dementia often display both agitated behavior and poor sleep." | 2.74 | Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. ( Ancoli-Israel, S; Connor, DJ; Corey-Bloom, J; Gehrman, PR; Martin, JL; Shochat, T, 2009) |
| "Ferulic acid (FA) is a phenol derivative from natural sources and serves as a potential pharmacophore that exerts multiple pharmacological properties such as antioxidant, neuroprotection, Aβ aggregation modulation, and anti-inflammatory." | 2.72 | A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease. ( Kumar, S; Mishra, S; Modi, G; Rai, H; Singh, G; Singh, GK; Singh, YP; Srikrishna, S, 2021) |
| "In the setting of Alzheimer's disease, insomnia is an even more complicated issue, with a higher overall prevalence than in the general population, greater complexity of contributing etiologies, and differences in diagnosis (at times based on caregiver observation of sleep disruption rather than subjective complaints by the individual with the disorder), and requiring more discretion in terms of treatment, particularly in regard to adverse effect profile concerns." | 2.72 | Impact of Pharmacotherapy on Insomnia in Patients with Alzheimer's Disease. ( Bliwise, DL; Roland, JP, 2021) |
| "Brain disorders such as Alzheimer's and Parkinson's disease (PD) are irreversible conditions with several cognitive problems, including learning disabilities, memory loss, movement abnormalities, and speech problems." | 2.72 | Melatonin hormone as a therapeutic weapon against neurodegenerative diseases. ( Alghamdi, S; Almehmadi, M; Asefy, Z; Dablool, AS; Eftekhari, A; Hoseinnejhad, S; Kazemi, E; Khusro, A; Mammadova, S; Sahibzada, MUK, 2021) |
| "Melatonin (MLT) is a neurohormone that is regulated by the circadian clock and plays multifunctional roles in numerous neurodegenerative disorders, such as Alzheimer's disease (AD)." | 2.72 | Exploring the multifunctional role of melatonin in regulating autophagy and sleep to mitigate Alzheimer's disease neuropathology. ( Chen, R; Hossain, MF; Li, S; Li, Z; Lim, LW; Roy, J; Song, YQ; Uddin, MG; Wang, N, 2021) |
| "The search for new Alzheimer's disease (AD) cerebrospinal fluid (CSF) and blood biomarkers with potential pathophysiological and clinical relevance continues, as new biomarkers might lead to improved early and differential diagnosis, monitoring of disease progression and might even identify new druggable targets." | 2.72 | Melatonin levels in the Alzheimer's disease continuum: a systematic review. ( Engelborghs, S; Nous, A; Smolders, I, 2021) |
| "Alzheimer's disease is a neurodegenerative disorder associated with age, and is characterized by pathological markers such as amyloid-beta plaques and neurofibrillary tangles." | 2.72 | Regulation of Melatonin and Neurotransmission in Alzheimer's Disease. ( Fung, ML; Lim, LW; Ng, J; Roy, J; Tsui, KC, 2021) |
| "to determine the efficacy of melatonin to treat SD in AD." | 2.72 | Melatonin and Sleep Disturbances in Alzheimer's Disease. ( Cavestro, C; Islam, MA; Kamal, MA; Prodhan, AHMSU, 2021) |
| "Subjects with Alzheimer's disease and nighttime sleep disturbance were randomly assigned to 1 of 3 treatment groups: placebo, 2." | 2.71 | A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. ( Gamst, A; Grundman, M; Kaye, J; Schafer, K; Singer, C; Thal, LJ; Thomas, R; Tractenberg, RE, 2003) |
| "Neurodegenerative diseases are the second most common cause of death and characterized by progressive impairments in movement or mental functioning in the central or peripheral nervous system." | 2.66 | Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases. ( Chen, D; Lee, TH; Zhang, T, 2020) |
| "Melatonin is a neuroendocrine hormone mainly synthesized in the pineal gland and exhibits a wide range of biological functions, such as sleep control, regulating circadian rhythm, immune enhancement, metabolism regulation, antioxidant, anti-aging, and anti-tumor effects." | 2.66 | Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases. ( Akbar, M; Luo, F; Rungratanawanich, W; Sandhu, AF; Song, BJ; Wang, X; Williams, GE; Zhou, S, 2020) |
| "Emerging evidence suggests that sleep deprivation (SD) and circadian rhythm disruption (CRD) may interact and increase the risk for the development of Alzheimer's disease (AD)." | 2.61 | The role of sleep deprivation and circadian rhythm disruption as risk factors of Alzheimer's disease. ( Chang, RC; Dunnett, S; Ho, YS; Wu, H, 2019) |
| "Melatonin has been reported to have multiple roles in the central nervous system (CNS), including improving neurogenesis and synaptic plasticity, suppressing neuroinflammation, enhancing memory function, and protecting against oxidative stress." | 2.61 | Pineal gland dysfunction in Alzheimer's disease: relationship with the immune-pineal axis, sleep disturbance, and neurogenesis. ( Song, J, 2019) |
| "Melatonin is an endocrine hormone, secreted during darkness, derived from tryptophan, and produced mainly by the pineal gland." | 2.58 | Multi-Faceted Role of Melatonin in Neuroprotection and Amelioration of Tau Aggregates in Alzheimer's Disease. ( Balmik, AA; Chinnathambi, S, 2018) |
| "Melatonin is a neurohormone mainly released by the pineal gland in a circadian manner and it regulates brain functions in various manners." | 2.58 | Melatonin in Synaptic Impairments of Alzheimer's Disease. ( Fang, YY; Jiang, Q; Lu, Y; Shi, Y; Tang, N; Tian, Q; Wei, YP; Zeng, P, 2018) |
| "Memantine is an uncompetitive N-methyl-d-aspartic acid receptor antagonist and is approved for the management of moderate-to-severe AD." | 2.53 | Pharmacotherpy and Alzheimer's Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach. ( Daulatzai, MA, 2016) |
| "Melatonin is an endogenously produced hormone in the brain and decreases during aging and in patients with AD." | 2.49 | Melatonin in Alzheimer's disease. ( Chu, J; Huang, QX; Lin, L; Tian, Q; Wang, JZ; Yang, SS, 2013) |
| "Melatonin is an endogenously produced and multifunctioning molecule that could theoretically intervene at any of a number of sites to abate the changes associated with the development of AD." | 2.48 | Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. ( Acuña-Castroviejo, D; Boga, JA; Coto-Montes, A; Fuentes-Broto, L; Korkmaz, A; Ma, S; Manchester, LC; Reiter, RJ; Rosales-Corral, SA; Tan, DX, 2012) |
| "Search terms were "Alzheimer" "mild cognitive impairment" and "melatonin"." | 2.47 | The use of chronobiotics in the resynchronization of the sleep/wake cycle. Therapeutical application in the early phases of Alzheimer's disease. ( Brusco, LI; Cardinali, DP; Furio, AM, 2011) |
| "Melatonin is an indolamine with a large spectrum of functions that can be divided into chronobiotic and nonchronobiotic." | 2.47 | Relevance of the chronobiological and non-chronobiological actions of melatonin for enhancing therapeutic efficacy in neurodegenerative disorders. ( Cecon, E; Markus, RP, 2011) |
| "Sleep and wake in Alzheimer's disease (AD) are often fragmented as manifested by bouts of wakefulness at night and napping during the day." | 2.46 | Non-pharmacologic management of sleep disturbance in Alzheimer's disease. ( David, R; Friedman, L; Noda, A; O'Hara, R; Robert, P; Yesavage, JA; Zeitzer, J, 2010) |
| "Melatonin is a hormone with indolaminic structure, produced in the pineal gland during darkness, with chronobiological activity that has been known for decades." | 2.44 | [Melatonina: old molecule, new medicament]. ( Fernández-Tresguerres Hernández, JA, 2008) |
| "Circadian rhythm disturbances, such as sleep disorders, are frequently seen in aging and are even more pronounced in Alzheimer's disease (AD)." | 2.44 | Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. ( Swaab, DF; Wu, YH, 2007) |
| "Melatonin not only plays an important role in the regulation of circadian rhythms, but also acts as antioxidant and neuroprotector that may be of importance in aging and Alzheimer's disease (AD)." | 2.43 | The human pineal gland and melatonin in aging and Alzheimer's disease. ( Swaab, DF; Wu, YH, 2005) |
| "Melatonin has been shown to be effective in arresting neurodegenerative phenomena seen in experimental models of Alzheimer's disease, Parkinsonism and ischemic stroke." | 2.43 | Role of melatonin in neurodegenerative diseases. ( Cardinali, DP; Esquifino, AI; Hardeland, R; Maestroni, GJ; Pandi-Perumal, SR; Srinivasan, V, 2005) |
| "Patients with dementias, such as Alzheimer's disease (AD), often have nocturnally disrupted sleep." | 2.42 | Sleep disorders in Alzheimer's disease and other dementias. ( Bliwise, DL, 2004) |
| "Melatonin is a hormone and antioxidant produced by the pineal gland of which four neurobiological roles have been claimed in the aged population: anti-ageing agent; free-radical scavenger; regulator of circadian rhythm; endogeneous sleep-inducer." | 2.41 | Melatonin in elderly patients with insomnia. A systematic review. ( Olde Rikkert, MG; Rigaud, AS, 2001) |
| "Melatonin treatment improved sleep quality and suppressed sundowning." | 2.41 | The use of melatonin in Alzheimer's disease. ( Brusco, LI; Cardinali, DP; Furio, AM; Liberczuk, C, 2002) |
| "Melatonin has several functions in terms of its antioxidative ability." | 2.40 | Suppression of oxygen toxicity by melatonin. ( Qi, WB; Reiter, RJ; Tan, DX, 1998) |
| "Melatonin has been shown to be highly effective in reducing oxidative damage in the central nervous system; this efficacy derives from its ability to directly scavenge a number of free radicals and to function as an indirect antioxidant." | 2.40 | Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism. ( Cabrera, J; Manchester, LC; Mayo, JC; Reiter, RJ; Sainz, RM; Tan, DX, 1999) |
| "Melatonin plays a protective role against Aβ-induced inflammation via an inflammasome-associated mechanism that is essential in inducing the active forms of cytokines and pyroptosis." | 1.91 | The role of melatonin in amyloid beta-induced inflammation mediated by inflammasome signaling in neuronal cell lines. ( Boontor, A; Govitrapong, P; Kutpruek, S; Nopparat, C, 2023) |
| "Melatonin receptors have been reported to associate with aging and AD, and their expression decreased with the progression of AD." | 1.72 | Activation of melatonin receptor 1 by CRISPR-Cas9 activator ameliorates cognitive deficits in an Alzheimer's disease mouse model. ( Kim, J; Park, H, 2022) |
| "Melatonin has been shown to prevent tau hyperphosphorylation in cellular and animal models." | 1.72 | Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer's disease. ( Chen, D; Gan, CL; Gu, X; Hu, L; Lan, G; Lee, TH; Li, R; Mei, Y; Shui, X; Tian, Y; Wang, L; Xia, Y; Zhang, M; Zhang, T, 2022) |
| "The typical symptoms of patients with Alzheimer's disease (AD) are amyloid-β (Aβ) plaques and tau hyperphosphorylation." | 1.72 | Astrocyte Dysregulation and Calcium Ion Imbalance May Link the Development of Osteoporosis and Alzheimer's Disease. ( Tsai, YL; Wang, YF; Yen, CT, 2022) |
| "Pretreatment with melatonin significantly reversed METH-induced APP-cleaving secretases and Aβ production." | 1.72 | Melatonin Attenuates Methamphetamine-Induced Alteration of Amyloid β Precursor Protein Cleaving Enzyme Expressions via Melatonin Receptor in Human Neuroblastoma Cells. ( Boontor, A; Govitrapong, P; Nopparat, C; Panmanee, J, 2022) |
| "Melatonin treatment reversed the abnormal expression of proteins in the signaling pathway of lysosomes, pathologic phagocytosis of microglia, and mitochondrial energy metabolism." | 1.62 | Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer's disease. ( Chen, C; Huang, X; Li, S; Liu, GP; Liu, J; Wang, J; Yang, C; Yang, X; Yu, H; Zhang, Z, 2021) |
| "Rosacea is significantly associated with dementia, particularly Alzheimer's disease (AD)." | 1.62 | Bioinformatics and Network Pharmacology Identify the Therapeutic Role and Potential Mechanism of Melatonin in AD and Rosacea. ( Deng, Z; Li, J; Li, Y; Wang, Y; Xie, H; Xu, S; Yan, S; Yang, X; Zhang, H; Zhang, Y, 2021) |
| "Melatonin was discovered more than 60 years ago." | 1.62 | Melatonin controversies, an update. ( Boutin, JA; Jockers, R, 2021) |
| " The effects of these five neuromodulators on Alzheimer's disease (AD) are briefly examined in this paper, and it is hypothesized that each of the five molecules has a u-shaped (or Janus-faced) dose-response curve, wherein too little or too much signaling is pathological in AD and possibly other diseases." | 1.62 | Norepinephrine May Oppose Other Neuromodulators to Impact Alzheimer's Disease. ( Fitzgerald, PJ, 2021) |
| "Melatonin is a neurohormone that has been shown to be protective in Alzheimer's diseases against amyloid-β (Aβ) toxicity, which involves interaction of Aβ with neuronal membrane." | 1.56 | The effects of melatonin, serotonin, tryptophan and NAS on the biophysical properties of DPPC monolayers. ( Lee, BY; Leonenko, Z; Robinson, M; Turnbull, S, 2020) |
| "In this study, we tested several sleep deprivation protocols (mechanical shakes and light interruptions) on Drosophila and delineated their influences on Drosophila sleep." | 1.56 | Screening of sleep assisting drug candidates with a Drosophila model. ( Ma, WW; Peng, IF; Wang, YY, 2020) |
| " Further drug-like property analysis demonstrated that the optimized compound, 8d (WI-1758), had liver microsomal metabolic stability, was well tolerated (>2000 mg/kg), and had a rational pharmacokinetic profile, as well as an oral bioavailability of 14." | 1.48 | Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease. ( Chan, ASC; Feng, X; Hu, J; Huang, L; Li, X; Wang, Z; Yang, X, 2018) |
| "Novel multifunctional tacrines for Alzheimer's disease were obtained by Ugi-reaction between ferulic (or lipoic acid), a melatonin-like isocyanide, formaldehyde, and tacrine derivatives, according to the antioxidant additive approach in order to modulate the oxidative stress as therapeutic strategy." | 1.43 | The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators. ( Bautista-Aguilera, OM; Benchekroun, M; Buendía, I; Egea, J; Ismaili, L; Janockova, J; Jimeno, ML; Jun, D; León, R; Marco-Contelles, J; Michalska, P; Ouari, O; Refouvelet, B; Romero, A; Sepsova, V; Soukup, O, 2016) |
| "Melatonin is a neurohormone whose levels are significantly reduced or absent in Alzheimer's disease (AD) patients." | 1.43 | Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures. ( Buendia, I; Egea, J; León, R; López, MG; Navarro, E; Negredo, P; Parada, E, 2016) |
| "Translational research on Alzheimer's disease (AD) has often focused on reducing the high cerebral levels of amyloid-β (Aβ) as a key characteristic of AD pathogenesis." | 1.42 | Melatonin attenuates impairments of structural hippocampal neuroplasticity in OXYS rats during active progression of Alzheimer's disease-like pathology. ( Kiseleva, E; Kolosova, NG; Maksimova, KY; Muraleva, NA; Rudnitskaya, EA; Stefanova, NA, 2015) |
| "Similarly, amyloid plaque loads in hippocampus and frontal cortex, as well as plasma Aβ1-42 levels, were significantly reduced by MEL in a receptor-independent manner, in contrast to MEL's efficacy in reducing cortical antioxidant gene expression (Catalase, SOD1, Glutathione Peroxidase-1, Nrf2) only when receptors were present." | 1.42 | Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPP(swe)/PS1 mice. ( Bradshaw, PC; Delic, V; O'Neal-Moffitt, G; Olcese, J, 2015) |
| "Melatonin is a multifunctional molecule and plays a crucial role in the regulation of circadian rhythms." | 1.42 | Melatonin Attenuates Memory Impairment, Amyloid-β Accumulation, and Neurodegeneration in a Rat Model of Sporadic Alzheimer's Disease. ( Kiseleva, E; Kolosova, NG; Maksimova, KY; Muraleva, NA; Rudnitskaya, EA; Stefanova, NA, 2015) |
| "The current therapies for Alzheimer's disease (AD) are merely palliative that cannot arrest the pathologic progression of the disease." | 1.39 | Disease-modified glycogen synthase kinase-3β intervention by melatonin arrests the pathology and memory deficits in an Alzheimer's animal model. ( Hong, XP; Hu, J; Liu, D; Peng, CX; Wang, JZ; Wu, YY; Zhu, LQ, 2013) |
| "Melatonin was effective in the memory facilitating effects only when administered in the afternoon." | 1.39 | A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease. ( He, P; Laudon, M; Ouyang, X; Tang, C; Tian, S; Yin, W; Zhou, S, 2013) |
| "The tacrine fragment was selected for its inhibition of cholinesterases, and the flavonoid scaffold derived from 4-oxo-4H -chromene was chosen for its radical capture and β-secretase 1 (BACE-1) inhibitory activities." | 1.38 | New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties. ( Fernández-Bachiller, MI; Monjas, L; Pérez, C; Rademann, J; Rodríguez-Franco, MI, 2012) |
| "The cascade of events that occurs in Alzheimer's disease involving oxidative stress and the reduction in cholinergic transmission can be better addressed by multifunctional drugs than cholinesterase inhibitors alone." | 1.38 | Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease. ( Finkin-Groner, E; Ginsburg, I; Lerman, L; Nudelman, A; Shalom, H; Weill, T; Weinstock, M; Yanovsky, I; Zaikin, A; Zeeli, S, 2012) |
| "Melatonin was effective against the immunosenescence that 3xTg-AD mice present." | 1.38 | Melatonin plus physical exercise are highly neuroprotective in the 3xTg-AD mouse. ( Acuña-Castroviejo, D; Cristòfol, R; Escames, G; García-Mesa, Y; Giménez-Llort, L; López, LC; Sanfeliu, C; Venegas, C, 2012) |
| "Melatonin treatment yielded a near complete restoration of mitochondrial function in assays of respiratory rate, membrane potential, reactive oxygen species production, and ATP levels." | 1.38 | Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells. ( Arendash, GW; Bradshaw, PC; Cao, C; Copes, N; Delic, V; Dragicevic, N; Lin, X; Mamcarz, M; Wang, L, 2012) |
| "Delirium is a common and serious acute neuropsychiatric syndrome characterized by inattention and global cognitive dysfunction." | 1.38 | Marked improvement in delirium with ramelteon: five case reports. ( Furuya, M; Horiguchi, J; Miyaoka, T; Otsuka, S; Tanaka, I; Wake, R; Yamashita, S; Yasuda, H, 2012) |
| "Melatonin is a hormone synthesized from the neurotransmitter serotonin and is found mainly in the pineal gland." | 1.36 | A potential role for crystallization inhibitors in treatment of Alzheimer's disease. ( Costa-Bauzà, A; Grases, F; Prieto, RM, 2010) |
| "Melatonin is a potent antioxidant and the loss of its protection in the cerebrospinal fluid in Alzheimer's disease can explain the pattern of cell destruction." | 1.36 | Choroid plexus portals and a deficiency of melatonin can explain the neuropathology of Alzheimer's disease. ( Maurizi, CP, 2010) |
| "Sleep in older adults with Alzheimer's disease can often be extremely fragmented, thus disturbing normal sleep-wake rhythms." | 1.36 | Sleep in older adults with Alzheimer's disease. ( Dowling, GA; Lee, KA; Song, Y; Strawbridge, WJ; Wallhagen, MI, 2010) |
| "Most patients with Alzheimer's disease (AD) present decreased levels of melatonin, a day-night rhythm-related hormone." | 1.35 | Constant illumination induces Alzheimer-like damages with endoplasmic reticulum involvement and the protection of melatonin. ( Fu, ZQ; Ling, ZQ; Tian, Q; Wang, JZ; Wang, L; Wang, Q; Wang, XC, 2009) |
| "Melatonin was successfully used as an alternative treatment." | 1.35 | REM sleep behaviour disorder treated with melatonin in a patient with Alzheimer's disease. ( Anderson, KN; Graham, AJ; Jamieson, S; Shneerson, JM, 2008) |
| "Melatonin was given in addition to the standard medication prescribed by the attending psychiatrist." | 1.34 | Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. ( Brusco, LI; Cardinali, DP; Furio, AM, 2007) |
| "Melatonin is a potent endogenous antioxidant and free radical scavenger." | 1.33 | Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. ( Chang, Y; Feng, Z; Qin, C; Zhang, JT, 2006) |
| "Melatonin is a product that plays not only a major role in the regulation of the circadian rhythms but may also exert neuroprotective effects in AD." | 1.32 | Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. ( Hofman, MA; Kamphorst, W; Liu, RY; Swaab, DF; Zhou, JN, 2003) |
| "Melatonin is an endogenous antioxidant and free radical scavenger." | 1.32 | Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. ( Chang, Y; Cheng, Y; Feng, Z; Qin, C; Qu, ZW; Zhang, BL; Zhang, JT, 2004) |
| "Melatonin is an endogenously generated potent antioxidant." | 1.32 | Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats. ( Cheng, Y; Feng, Z; Zhang, JT, 2004) |
| "Melatonin is a potent antioxidant and free radical scavenger." | 1.32 | Protective effect of melatonin on beta-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism. ( Feng, Z; Zhang, JT, 2004) |
| "The melatonin metabolite was inversely correlated with A beta (1-42) and the ratio of A beta (1-42) to A beta (1-40)." | 1.31 | Relationship between amyloid beta protein and melatonin metabolite in a study of electric utility workers. ( Burch, JB; Ichinose, TY; Magnusson, K; Noonan, CW; Reif, JS; Yost, MG, 2002) |
| "Melatonin was found to prevent significantly the decline of T-SOD, CuZn-SOD and GSH-Px activities, the increase of MDA content in the cortex and hippocampus of mouse brain induced by aluminum chloride." | 1.31 | [Effect of melatonin on learning and memory impairment induced by aluminum chloride and its mechanism]. ( Yu, CX; Zhang, Z, 2002) |
| "1." | 1.31 | Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei. ( Brusco, LL; Caccuri, RL; Cardinali, DP; Castillo Thea, V; Cutrera, RA; Furio, AM; Pérez Lloret, S; Riccio, P, 2002) |
| "Neurodegeneration in Alzheimer's disease (AD) is associated with many features of the immune system." | 1.31 | Melatonin reduces interleukin secretion in amyloid-beta stressed mouse brain slices. ( Clapp-Lilly, KL; Duffy, LK; Perry, G; Smith, MA, 2001) |
| " Chronic administration of melatonin (0." | 1.31 | Possible antioxidant mechanism in melatonin reversal of aging and chronic ethanol-induced amnesia in plus-maze and passive avoidance memory tasks. ( Kulkarni, SK; Raghavendra, V, 2001) |
| "Melatonin pre-treatment reversed the deleterious effects of cobalt." | 1.31 | Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion. ( Baysang, G; Brockhaus, M; Hess, C; Ly, C; Meier, F; Müller-Spahn, F; Olivieri, G; Savaskan, E, 2001) |
| " Al and A beta 25-35 caused lipid peroxidation in the presence of the iron (II) ion (Pe2+), Al being more toxic than A beta 25-35." | 1.30 | A new model for the pathophysiology of Alzheimer's disease. Aluminium toxicity is exacerbated by hydrogen peroxide and attenuated by an amyloid protein fragment and melatonin. ( Daniels, WM; Emsley, RA; Potocnik, FC; Taljaard, JJ; van Rensburg, SJ; van Zyl, JM, 1997) |
| "Monozygotic twins with Alzheimer's disease of 8 years duration were studied." | 1.30 | Monozygotic twins with Alzheimer's disease treated with melatonin: Case report. ( Brusco, LI; Cardinali, DP; Márquez, M, 1998) |
| "Most contemporary progress in Alzheimer's disease (AD) stems from the study of a 42 43 amino acid peptide." | 1.30 | Alzheimer beta protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin. ( Bozner, P; Chyan, YJ; Ghiso, J; LeDoux, SP; Pappolla, MA; Poeggeler, B; Wilson, GL, 1999) |
| " The results obtained warrant the further search for the novel types of safe neuroprotectors among the synthetic NAS/melatonin derivatives." | 1.30 | N-acetylserotonin, melatonin and their derivatives improve cognition and protect against beta-amyloid-induced neurotoxicity. ( Afanasiev, A; Bachurin, S; Beznosko, B; Lermontova, N; Mukhina, T; Oxenkrug, G; Serkova, T; Shevtzova, E; Vankin, G, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.36) | 18.7374 |
| 1990's | 22 (7.94) | 18.2507 |
| 2000's | 72 (25.99) | 29.6817 |
| 2010's | 108 (38.99) | 24.3611 |
| 2020's | 74 (26.71) | 2.80 |
| Authors | Studies |
|---|---|
| Rodríguez-Franco, MI | 10 |
| Fernández-Bachiller, MI | 3 |
| Pérez, C | 8 |
| Hernández-Ledesma, B | 1 |
| Bartolomé, B | 1 |
| Necula, M | 1 |
| Kayed, R | 1 |
| Milton, S | 1 |
| Glabe, CG | 1 |
| de Los Ríos, C | 3 |
| Egea, J | 7 |
| Marco-Contelles, J | 6 |
| León, R | 6 |
| Samadi, A | 2 |
| Iriepa, I | 5 |
| Moraleda, I | 5 |
| Gálvez, E | 1 |
| García, AG | 3 |
| López, MG | 7 |
| Villarroya, M | 5 |
| Romero, A | 6 |
| González-Muñoz, GC | 2 |
| Arce, MP | 2 |
| López, B | 1 |
| del Barrio, L | 1 |
| Martín-de-Saavedra, MD | 1 |
| Conde, S | 3 |
| Jiang, H | 2 |
| Wang, X | 4 |
| Huang, L | 2 |
| Luo, Z | 1 |
| Su, T | 1 |
| Ding, K | 1 |
| Li, X | 2 |
| Monjas, L | 3 |
| Rademann, J | 1 |
| Maalej, E | 1 |
| Chabchoub, F | 3 |
| Oset-Gasque, MJ | 2 |
| Esquivias-Pérez, M | 1 |
| González, MP | 1 |
| Chioua, M | 1 |
| Yanovsky, I | 1 |
| Finkin-Groner, E | 1 |
| Zaikin, A | 1 |
| Lerman, L | 1 |
| Shalom, H | 1 |
| Zeeli, S | 1 |
| Weill, T | 1 |
| Ginsburg, I | 1 |
| Nudelman, A | 1 |
| Weinstock, M | 1 |
| López-Iglesias, B | 1 |
| Morales-García, JA | 2 |
| Alonso-Gil, S | 1 |
| Pérez-Castillo, A | 2 |
| Li, Y | 5 |
| Peng, P | 1 |
| Tang, L | 1 |
| Hu, Y | 2 |
| Sheng, R | 1 |
| Luo, XT | 1 |
| Wang, CM | 1 |
| Liu, Y | 3 |
| Huang, ZG | 1 |
| Wang, J | 5 |
| Wang, ZM | 2 |
| Li, XM | 1 |
| Li, F | 3 |
| Wu, JJ | 4 |
| Kong, LY | 4 |
| Wang, XB | 4 |
| Cai, P | 3 |
| Liu, QH | 2 |
| Xu, DQ | 1 |
| Yang, XL | 3 |
| Benchekroun, M | 1 |
| Michalska, P | 1 |
| Buendía, I | 3 |
| Jimeno, ML | 1 |
| Jun, D | 1 |
| Janockova, J | 1 |
| Sepsova, V | 1 |
| Soukup, O | 2 |
| Bautista-Aguilera, OM | 1 |
| Refouvelet, B | 2 |
| Ouari, O | 1 |
| Ismaili, L | 4 |
| Espargaró, A | 1 |
| Ginex, T | 1 |
| Vadell, MD | 1 |
| Busquets, MA | 1 |
| Estelrich, J | 1 |
| Muñoz-Torrero, D | 1 |
| Luque, FJ | 1 |
| Sabate, R | 1 |
| Gil, C | 1 |
| Wang, Z | 1 |
| Hu, J | 2 |
| Yang, X | 5 |
| Feng, X | 1 |
| Chan, ASC | 1 |
| Estrada Valencia, M | 1 |
| Herrera-Arozamena, C | 1 |
| de Andrés, L | 1 |
| Ramos, E | 1 |
| Viña, D | 1 |
| Yáñez, M | 1 |
| Laurini, E | 1 |
| Pricl, S | 1 |
| Malek, R | 2 |
| Arribas, RL | 1 |
| Palomino-Antolin, A | 1 |
| Totoson, P | 1 |
| Demougeot, C | 1 |
| Kobrlova, T | 1 |
| Diez-Iriepa, D | 2 |
| Godyń, J | 1 |
| Panek, D | 1 |
| Malawska, B | 1 |
| Głuch-Lutwin, M | 1 |
| Mordyl, B | 1 |
| Siwek, A | 1 |
| Kiec-Kononowicz, K | 1 |
| Singh, YP | 1 |
| Rai, H | 1 |
| Singh, G | 1 |
| Singh, GK | 1 |
| Mishra, S | 1 |
| Kumar, S | 1 |
| Srikrishna, S | 1 |
| Modi, G | 1 |
| He, F | 1 |
| Chou, CJ | 1 |
| Scheiner, M | 1 |
| Poeta, E | 1 |
| Yuan Chen, N | 1 |
| Gunesch, S | 1 |
| Hoffmann, M | 1 |
| Sotriffer, C | 1 |
| Monti, B | 1 |
| Maurice, T | 1 |
| Decker, M | 1 |
| Jiang, MY | 1 |
| Han, C | 1 |
| Zhang, C | 2 |
| Zhou, Q | 2 |
| Zhang, B | 2 |
| Le, ML | 1 |
| Huang, MX | 1 |
| Wu, Y | 1 |
| Luo, HB | 1 |
| Roland, JP | 1 |
| Bliwise, DL | 2 |
| Chen, C | 1 |
| Yang, C | 2 |
| Huang, X | 2 |
| Yu, H | 2 |
| Li, S | 4 |
| Zhang, Z | 2 |
| Liu, J | 4 |
| Liu, GP | 1 |
| Le, B | 1 |
| White, ACG | 1 |
| Chaudhari, A | 1 |
| Al-Mutawaly, N | 1 |
| White, JE | 1 |
| Lee, WK | 1 |
| Hsu, YL | 1 |
| White, JD | 1 |
| Zhang, H | 1 |
| Zhang, Y | 3 |
| Wang, Y | 3 |
| Yan, S | 1 |
| Xu, S | 1 |
| Deng, Z | 1 |
| Xie, H | 1 |
| Li, J | 1 |
| Moderie, C | 1 |
| Carrier, J | 1 |
| Dang-Vu, TT | 1 |
| Asefy, Z | 1 |
| Khusro, A | 1 |
| Mammadova, S | 1 |
| Hoseinnejhad, S | 1 |
| Eftekhari, A | 1 |
| Alghamdi, S | 1 |
| Dablool, AS | 1 |
| Almehmadi, M | 1 |
| Kazemi, E | 1 |
| Sahibzada, MUK | 1 |
| Peng, X | 2 |
| Fan, R | 2 |
| Xie, L | 2 |
| Shi, X | 2 |
| Dong, K | 2 |
| Zhang, S | 6 |
| Tao, J | 1 |
| Xu, W | 2 |
| Ma, D | 2 |
| Chen, J | 2 |
| Yang, Y | 5 |
| Park, H | 1 |
| Kim, J | 2 |
| Roy, J | 4 |
| Wong, KY | 2 |
| Aquili, L | 2 |
| Uddin, MS | 3 |
| Heng, BC | 2 |
| Tipoe, GL | 1 |
| Wong, KH | 1 |
| Fung, ML | 3 |
| Lim, LW | 4 |
| Shen, S | 1 |
| Liao, Q | 1 |
| Wong, YK | 1 |
| Chen, X | 1 |
| Xu, C | 1 |
| Sun, J | 2 |
| Tseng, PT | 1 |
| Zeng, BY | 1 |
| Chen, YW | 1 |
| Yang, CP | 1 |
| Su, KP | 1 |
| Chen, TY | 1 |
| Wu, YC | 1 |
| Tu, YK | 1 |
| Lin, PY | 1 |
| Carvalho, AF | 1 |
| Stubbs, B | 1 |
| Matsuoka, YJ | 1 |
| Li, DJ | 1 |
| Liang, CS | 1 |
| Hsu, CW | 1 |
| Sun, CK | 1 |
| Cheng, YS | 1 |
| Yeh, PY | 1 |
| Shiue, YL | 1 |
| Abu-Elfotuh, K | 1 |
| Hussein, FH | 1 |
| Abbas, AN | 1 |
| Al-Rekabi, MD | 1 |
| Barghash, SS | 1 |
| Zaghlool, SS | 1 |
| El-Emam, SZ | 1 |
| Chen, D | 3 |
| Lan, G | 2 |
| Li, R | 1 |
| Mei, Y | 2 |
| Shui, X | 1 |
| Gu, X | 1 |
| Wang, L | 5 |
| Zhang, T | 3 |
| Gan, CL | 2 |
| Xia, Y | 2 |
| Hu, L | 1 |
| Tian, Y | 1 |
| Zhang, M | 1 |
| Lee, TH | 3 |
| Ravikumar, M | 1 |
| Mohan, S | 1 |
| Velpandian, C | 1 |
| Tsai, YL | 1 |
| Yen, CT | 1 |
| Wang, YF | 1 |
| Chen, T | 1 |
| Cao, M | 1 |
| Yuan, C | 1 |
| Reiter, RJ | 10 |
| Zhao, Z | 1 |
| Zhao, Y | 1 |
| Chen, L | 1 |
| Fan, W | 2 |
| Zhou, X | 1 |
| Li, C | 1 |
| Nopparat, C | 5 |
| Boontor, A | 2 |
| Panmanee, J | 1 |
| Govitrapong, P | 6 |
| Merlo, S | 1 |
| Caruso, GI | 1 |
| Bonfili, L | 1 |
| Spampinato, SF | 1 |
| Costantino, G | 1 |
| Eleuteri, AM | 1 |
| Sortino, MA | 1 |
| Majidazar, R | 1 |
| Rezazadeh-Gavgani, E | 1 |
| Sadigh-Eteghad, S | 1 |
| Naseri, A | 1 |
| Li, LB | 1 |
| Fan, YG | 1 |
| Wu, WX | 1 |
| Bai, CY | 1 |
| Jia, MY | 1 |
| Hu, JP | 1 |
| Gao, HL | 1 |
| Wang, T | 1 |
| Zhong, ML | 1 |
| Huang, XS | 1 |
| Guo, C | 1 |
| Yu, X | 2 |
| Zhai, Z | 1 |
| Xie, D | 1 |
| Qin, T | 1 |
| Zhong, Y | 1 |
| Xu, Y | 2 |
| Sun, T | 1 |
| Jiang, Y | 3 |
| Lin, Y | 3 |
| Tan, Y | 3 |
| Shen, X | 3 |
| Liao, M | 3 |
| Wang, H | 3 |
| Lu, N | 3 |
| Han, F | 3 |
| Xu, N | 3 |
| Tang, C | 4 |
| Song, J | 4 |
| Tao, R | 3 |
| Liu, P | 1 |
| Cheng, M | 1 |
| Guo, J | 1 |
| Cao, D | 1 |
| Luo, J | 2 |
| Wan, Y | 1 |
| Fang, Y | 1 |
| Jin, Y | 2 |
| Xie, SS | 1 |
| Wang, P | 3 |
| Hu, C | 2 |
| Ren, L | 2 |
| Bi, J | 2 |
| Yoo, YM | 1 |
| Joo, SS | 1 |
| Tchekalarova, J | 2 |
| Tzoneva, R | 1 |
| Fihurka, O | 1 |
| Hong, Y | 2 |
| Lin, X | 3 |
| Shen, N | 1 |
| Yang, H | 3 |
| Brown, B | 1 |
| Mommer, M | 1 |
| Zieneldien, T | 1 |
| Li, M | 2 |
| Cai, J | 1 |
| Cao, C | 4 |
| Sharma, R | 1 |
| Cucielo, MS | 1 |
| Tan, DX | 4 |
| Rosales-Corral, S | 1 |
| Gancitano, G | 1 |
| de Almeida Chuffa, LG | 1 |
| Shukla, M | 2 |
| Vincent, B | 2 |
| Loh, D | 1 |
| Sandoval, KE | 1 |
| Anderson, G | 2 |
| Khezri, MR | 1 |
| Esmaeili, A | 1 |
| Ghasemnejad-Berenji, M | 1 |
| Kutpruek, S | 1 |
| Feng, Y | 1 |
| Jiang, X | 1 |
| Liu, W | 1 |
| Lu, H | 1 |
| Maj, M | 1 |
| Wnorowski, A | 1 |
| Jóźwiak, K | 1 |
| Martin, H | 2 |
| Jürgenson, M | 1 |
| Zharkovskaja, T | 1 |
| Noortoots, A | 1 |
| Morozova, M | 1 |
| Beniashvili, A | 1 |
| Zapolski, M | 1 |
| Zharkovsky, A | 2 |
| Havekes, R | 1 |
| Heckman, PRA | 1 |
| Wams, EJ | 1 |
| Stasiukonyte, N | 1 |
| Meerlo, P | 1 |
| Eisel, ULM | 1 |
| Manni, R | 1 |
| Cremascoli, R | 1 |
| Perretti, C | 1 |
| De Icco, R | 1 |
| Picascia, M | 1 |
| Ghezzi, C | 1 |
| Cerri, S | 1 |
| Sinforiani, E | 1 |
| Terzaghi, M | 1 |
| Balmik, AA | 2 |
| Das, R | 1 |
| Dangi, A | 1 |
| Gorantla, NV | 1 |
| Marelli, UK | 1 |
| Chinnathambi, S | 2 |
| Kamsrijai, U | 1 |
| Wongchitrat, P | 2 |
| Satayavivad, J | 2 |
| Rong, K | 1 |
| Zheng, H | 2 |
| Yang, R | 1 |
| Liu, X | 2 |
| Li, L | 1 |
| Chen, N | 1 |
| Zhao, G | 1 |
| Gong, C | 1 |
| Deng, Y | 1 |
| Srivastava, AK | 1 |
| Roy Choudhury, S | 1 |
| Karmakar, S | 1 |
| Gonzalez, A | 1 |
| Cruz-Aguilar, MA | 2 |
| Ramírez-Salado, I | 2 |
| Hernández-González, M | 2 |
| Guevara, MA | 2 |
| Del Río, JM | 1 |
| Kim, N | 1 |
| Fan, F | 1 |
| Lin, C | 1 |
| Ke, F | 1 |
| Zhou, XZ | 1 |
| Lu, KP | 1 |
| Xu, L | 2 |
| Sun, H | 1 |
| Hu, B | 1 |
| Geng, Y | 1 |
| Robinson, M | 1 |
| Turnbull, S | 1 |
| Lee, BY | 1 |
| Leonenko, Z | 1 |
| Ramezani, M | 1 |
| Komaki, A | 1 |
| Hashemi-Firouzi, N | 2 |
| Mortezaee, K | 1 |
| Faraji, N | 1 |
| Golipoor, Z | 2 |
| Sun, C | 1 |
| Qiu, X | 1 |
| Li, Q | 1 |
| Song, C | 2 |
| Mihardja, M | 1 |
| Chan, YS | 1 |
| Wang, YY | 2 |
| Ma, WW | 1 |
| Peng, IF | 1 |
| Mueed, Z | 1 |
| Rai, PK | 1 |
| Kamal, MA | 2 |
| Poddar, NK | 1 |
| Liu, YC | 1 |
| Hsu, WL | 1 |
| Ma, YL | 1 |
| Lee, EHY | 1 |
| Luo, F | 1 |
| Sandhu, AF | 1 |
| Rungratanawanich, W | 1 |
| Williams, GE | 1 |
| Akbar, M | 1 |
| Zhou, S | 2 |
| Song, BJ | 1 |
| Boutin, JA | 1 |
| Jockers, R | 3 |
| McCleery, J | 3 |
| Sharpley, AL | 3 |
| Zhang, J | 2 |
| Wan, J | 1 |
| Liu, A | 1 |
| Labban, S | 1 |
| Alghamdi, BS | 1 |
| Alshehri, FS | 1 |
| Kurdi, M | 1 |
| Hossain, MF | 2 |
| Wang, N | 1 |
| Chen, R | 1 |
| Uddin, MG | 1 |
| Li, Z | 2 |
| Song, YQ | 1 |
| Nous, A | 2 |
| Engelborghs, S | 2 |
| Smolders, I | 2 |
| Chaopae, W | 1 |
| Boontem, P | 2 |
| Sopha, P | 1 |
| Sumsuzzman, DM | 3 |
| Jeandet, P | 1 |
| Behl, T | 1 |
| Rauf, A | 1 |
| Amran, MS | 1 |
| Ashraf, GM | 2 |
| Choi, J | 1 |
| Rivera-García, AP | 1 |
| Kim, SJ | 1 |
| Lee, SH | 1 |
| Suh, IB | 1 |
| Jang, JW | 1 |
| Jhoo, JH | 1 |
| Lee, JH | 1 |
| Tsui, KC | 1 |
| Ng, J | 1 |
| Panmak, P | 1 |
| Permpoonpattana, K | 1 |
| Namyen, J | 1 |
| Fitzgerald, PJ | 1 |
| Prodhan, AHMSU | 1 |
| Cavestro, C | 1 |
| Islam, MA | 1 |
| Wittens, MMJ | 1 |
| Vermeiren, Y | 1 |
| De Deyn, PP | 1 |
| Van Broeckhoven, C | 1 |
| Nagels, G | 1 |
| Dai, Y | 1 |
| Peng, L | 1 |
| Qiao, J | 1 |
| Saeed, Y | 1 |
| Abbott, SM | 1 |
| Lv, Y | 1 |
| Yin, R | 1 |
| Mendivil-Perez, M | 1 |
| Soto-Mercado, V | 1 |
| Guerra-Librero, A | 1 |
| Fernandez-Gil, BI | 1 |
| Florido, J | 1 |
| Shen, YQ | 1 |
| Tejada, MA | 1 |
| Capilla-Gonzalez, V | 1 |
| Rusanova, I | 1 |
| Garcia-Verdugo, JM | 1 |
| Acuña-Castroviejo, D | 3 |
| López, LC | 2 |
| Velez-Pardo, C | 1 |
| Jimenez-Del-Rio, M | 1 |
| Ferrer, JM | 1 |
| Escames, G | 2 |
| Zuev, VA | 1 |
| Trifonov, NI | 1 |
| Linkova, NS | 1 |
| Kvetnaia, TV | 1 |
| Nie, L | 1 |
| Wei, G | 1 |
| Peng, S | 1 |
| Qu, Z | 1 |
| Yang, Q | 1 |
| Zhuang, Z | 1 |
| Gong, YH | 1 |
| Hua, N | 1 |
| Zang, X | 1 |
| Huang, T | 1 |
| He, L | 1 |
| Hurley, MJ | 1 |
| Deacon, RMJ | 1 |
| Beyer, K | 1 |
| Ioannou, E | 1 |
| Ibáñez, A | 1 |
| Teeling, JL | 1 |
| Cogram, P | 1 |
| Shi, Y | 1 |
| Fang, YY | 1 |
| Wei, YP | 1 |
| Jiang, Q | 1 |
| Zeng, P | 1 |
| Tang, N | 1 |
| Lu, Y | 1 |
| Tian, Q | 5 |
| Zverova, M | 1 |
| Kitzlerova, E | 1 |
| Fisar, Z | 1 |
| Jirak, R | 1 |
| Hroudova, J | 1 |
| Benakova, H | 1 |
| Lelkova, P | 1 |
| Martasek, P | 1 |
| Raboch, J | 1 |
| Sulkava, S | 1 |
| Muggalla, P | 1 |
| Sulkava, R | 1 |
| Ollila, HM | 1 |
| Peuralinna, T | 1 |
| Myllykangas, L | 1 |
| Kaivola, K | 1 |
| Stone, DJ | 1 |
| Traynor, BJ | 1 |
| Renton, AE | 1 |
| Rivera, AM | 1 |
| Helisalmi, S | 1 |
| Soininen, H | 1 |
| Polvikoski, T | 1 |
| Hiltunen, M | 1 |
| Tienari, PJ | 1 |
| Huttunen, HJ | 1 |
| Paunio, T | 1 |
| Shen, Y | 1 |
| Ding, M | 2 |
| Xie, Z | 1 |
| Spinedi, E | 1 |
| Cardinali, DP | 9 |
| Ilieva, K | 1 |
| Atanasova, D | 1 |
| Kortenska, L | 1 |
| Atanasova, M | 1 |
| Fang, J | 1 |
| Li, YH | 1 |
| Li, XH | 1 |
| Chen, WW | 1 |
| He, J | 1 |
| Xue, MZ | 1 |
| Pachón-Angona, I | 1 |
| Andrýs, R | 1 |
| Luzet, V | 1 |
| Musilek, K | 1 |
| Tobore, TO | 1 |
| Wang, CF | 1 |
| Song, CY | 1 |
| Huang, LY | 1 |
| Xu, LL | 1 |
| Xie, ZH | 1 |
| Bi, JZ | 1 |
| Wu, H | 1 |
| Dunnett, S | 1 |
| Ho, YS | 1 |
| Chang, RC | 1 |
| Nasiri, E | 1 |
| Alizadeh, A | 1 |
| Roushandeh, AM | 1 |
| Gazor, R | 1 |
| Uddin, GMS | 1 |
| Islam, MS | 1 |
| Barreto, GE | 1 |
| Mathew, B | 1 |
| Khatoon, R | 1 |
| Rasheed, MZ | 1 |
| Rawat, M | 1 |
| Alam, MM | 1 |
| Tabassum, H | 1 |
| Parvez, S | 1 |
| Peng, CX | 1 |
| Liu, D | 1 |
| Hong, XP | 1 |
| Wu, YY | 1 |
| Zhu, LQ | 2 |
| Wang, JZ | 10 |
| He, P | 1 |
| Ouyang, X | 1 |
| Yin, W | 1 |
| Laudon, M | 2 |
| Tian, S | 1 |
| Lammers, M | 1 |
| Ahmed, AIA | 1 |
| Lin, L | 1 |
| Huang, QX | 1 |
| Yang, SS | 1 |
| Chu, J | 1 |
| de Jonghe, A | 1 |
| van Munster, BC | 1 |
| de Rooij, SE | 1 |
| Cohen, DA | 2 |
| Di Paolo, C | 1 |
| Reverte, I | 1 |
| Colomina, MT | 2 |
| Domingo, JL | 3 |
| Gómez, M | 3 |
| Song, TY | 1 |
| Lin, HC | 1 |
| Chen, CL | 1 |
| Wu, JH | 1 |
| Liao, JW | 1 |
| Hu, ML | 1 |
| Chojnacki, JE | 2 |
| Liu, K | 2 |
| Yan, X | 1 |
| Toldo, S | 1 |
| Selden, T | 1 |
| Estrada, M | 1 |
| Halquist, MS | 1 |
| Ye, D | 1 |
| Wade, AG | 1 |
| Farmer, M | 1 |
| Harari, G | 1 |
| Fund, N | 1 |
| Nir, T | 1 |
| Frydman-Marom, A | 1 |
| Zisapel, N | 2 |
| Parada, E | 2 |
| Navarro, E | 2 |
| Ali, T | 1 |
| Badshah, H | 1 |
| Kim, TH | 1 |
| Kim, MO | 1 |
| Rudnitskaya, EA | 3 |
| Maksimova, KY | 3 |
| Muraleva, NA | 3 |
| Logvinov, SV | 1 |
| Yanshole, LV | 1 |
| Kolosova, NG | 3 |
| Stefanova, NA | 3 |
| Maes, M | 1 |
| Xu, J | 1 |
| Wang, LL | 1 |
| Dammer, EB | 1 |
| Li, CB | 1 |
| Xu, G | 1 |
| Chen, SD | 1 |
| Wang, G | 1 |
| Raggi, A | 1 |
| Neri, W | 1 |
| Ferri, R | 1 |
| Gerenu, G | 1 |
| Saathoff, JM | 1 |
| Martínez-Martín, P | 1 |
| Perry, G | 4 |
| Zhu, X | 2 |
| Lee, HG | 1 |
| Kiseleva, E | 2 |
| Negredo, P | 1 |
| O'Neal-Moffitt, G | 2 |
| Delic, V | 2 |
| Bradshaw, PC | 3 |
| Olcese, J | 1 |
| Yin, Y | 1 |
| Zhuang, J | 1 |
| Pan, X | 1 |
| Li, P | 1 |
| Li, YP | 1 |
| Zhao, ZQ | 1 |
| Huang, LQ | 1 |
| Zhao, ZX | 1 |
| Weissová, K | 1 |
| Bartoš, A | 1 |
| Sládek, M | 1 |
| Nováková, M | 1 |
| Sumová, A | 1 |
| Sirin, FB | 1 |
| Kumbul Doğuç, D | 1 |
| Vural, H | 1 |
| Eren, I | 1 |
| Inanli, I | 1 |
| Sütçü, R | 1 |
| Delibaş, N | 2 |
| Daulatzai, MA | 1 |
| Lim, Y | 1 |
| Cho, H | 1 |
| Kim, EK | 1 |
| Zheng, W | 1 |
| Ng, CH | 1 |
| Ungvari, GS | 1 |
| Wei, W | 1 |
| Xiang, YT | 1 |
| Pillai, JA | 1 |
| Leverenz, JB | 1 |
| Gunasingh, MJ | 1 |
| Philip, JE | 1 |
| Ashok, BS | 2 |
| Kirubagaran, R | 1 |
| Jebaraj, WC | 2 |
| Davis, GD | 1 |
| Vignesh, S | 2 |
| Dhandayuthapani, S | 2 |
| Jayakumar, R | 2 |
| Masilamoni, JG | 1 |
| Jesudason, EP | 1 |
| Paul, SF | 1 |
| Benarroch, EE | 1 |
| Gehrman, PR | 1 |
| Connor, DJ | 1 |
| Martin, JL | 1 |
| Shochat, T | 1 |
| Corey-Bloom, J | 1 |
| Ancoli-Israel, S | 1 |
| Ling, ZQ | 2 |
| Fu, ZQ | 1 |
| Wang, XC | 4 |
| Wang, Q | 3 |
| Campillo, NE | 1 |
| Páez, JA | 1 |
| Usán, P | 1 |
| García-Palomero, E | 1 |
| Martínez, A | 1 |
| Garcia, T | 2 |
| Esparza, JL | 1 |
| Nogués, MR | 1 |
| Romeu, M | 1 |
| Fernández-Tresguerres Hernández, JA | 1 |
| Olcese, JM | 2 |
| Mori, T | 1 |
| Mamcarz, MB | 1 |
| Maxwell, A | 1 |
| Runfeldt, MJ | 1 |
| Zhang, G | 1 |
| Arendash, GW | 3 |
| Grases, F | 1 |
| Costa-Bauzà, A | 1 |
| Prieto, RM | 1 |
| Ribes, D | 1 |
| Cabré, M | 1 |
| Spuch, C | 1 |
| Antequera, D | 1 |
| Isabel Fernandez-Bachiller, M | 1 |
| Isabel Rodríguez-Franco, M | 1 |
| Carro, E | 1 |
| Dong, W | 1 |
| Huang, F | 1 |
| Cheng, S | 1 |
| Chen, Y | 1 |
| Zhang, W | 1 |
| Shi, H | 2 |
| He, H | 1 |
| Turner, PL | 1 |
| Van Someren, EJ | 2 |
| Mainster, MA | 1 |
| Maurizi, CP | 6 |
| Hoppe, JB | 1 |
| Frozza, RL | 1 |
| Horn, AP | 1 |
| Comiran, RA | 1 |
| Bernardi, A | 1 |
| Campos, MM | 1 |
| Battastini, AMO | 1 |
| Salbego, C | 1 |
| Lauterbach, EC | 1 |
| Victoroff, J | 1 |
| Coburn, KL | 1 |
| Shillcutt, SD | 1 |
| Doonan, SM | 1 |
| Mendez, MF | 1 |
| David, R | 1 |
| Zeitzer, J | 1 |
| Friedman, L | 1 |
| Noda, A | 1 |
| O'Hara, R | 1 |
| Robert, P | 1 |
| Yesavage, JA | 1 |
| Markus, RP | 2 |
| Silva, CL | 1 |
| Franco, DG | 1 |
| Barbosa, EM | 1 |
| Ferreira, ZS | 1 |
| Arushanian, EB | 1 |
| Fu, Z | 1 |
| Feng, J | 1 |
| Zhang, Q | 1 |
| Song, Y | 1 |
| Dowling, GA | 2 |
| Wallhagen, MI | 1 |
| Lee, KA | 1 |
| Strawbridge, WJ | 1 |
| Galanakis, PA | 1 |
| Bazoti, FN | 1 |
| Bergquist, J | 1 |
| Markides, K | 1 |
| Spyroulias, GA | 1 |
| Tsarbopoulos, A | 1 |
| Pizza, V | 1 |
| Agresta, A | 1 |
| D'Acunto, CW | 1 |
| Festa, M | 1 |
| Capasso, A | 1 |
| Dragicevic, N | 2 |
| Copes, N | 2 |
| Jin, J | 1 |
| Buzzeo, R | 1 |
| Mamcarz, M | 2 |
| Tan, J | 1 |
| Baksheev, VI | 1 |
| Kolomoets, NM | 1 |
| Bedrosian, TA | 1 |
| Herring, KL | 1 |
| Weil, ZM | 1 |
| Nelson, RJ | 1 |
| Furio, AM | 4 |
| Brusco, LI | 4 |
| Cecon, E | 1 |
| Rosales-Corral, SA | 1 |
| Coto-Montes, A | 1 |
| Boga, JA | 1 |
| Manchester, LC | 2 |
| Fuentes-Broto, L | 1 |
| Korkmaz, A | 1 |
| Ma, S | 1 |
| Morley, JE | 1 |
| Armbrecht, HJ | 1 |
| Farr, SA | 1 |
| Kumar, VB | 1 |
| García-Mesa, Y | 1 |
| Giménez-Llort, L | 1 |
| Venegas, C | 1 |
| Cristòfol, R | 1 |
| Sanfeliu, C | 1 |
| Pagano, ES | 1 |
| Scacchi Bernasconi, PA | 1 |
| Reynoso, R | 1 |
| Scacchi, P | 1 |
| Matsubara, E | 2 |
| Slats, D | 1 |
| Claassen, JA | 1 |
| Verbeek, MM | 1 |
| Overeem, S | 1 |
| Baño Otalora, B | 1 |
| Popovic, N | 1 |
| Gambini, J | 1 |
| Popovic, M | 1 |
| Viña, J | 1 |
| Bonet-Costa, V | 1 |
| Camello, PJ | 1 |
| Rol, MÁ | 1 |
| Madrid, JA | 1 |
| Raukas, M | 1 |
| Rebane, R | 1 |
| Mahlapuu, R | 1 |
| Jefremov, V | 1 |
| Zilmer, K | 1 |
| Karelson, E | 2 |
| Bogdanovic, N | 2 |
| Zilmer, M | 1 |
| Jun, Z | 1 |
| Fang, W | 1 |
| Fengzhen, Y | 1 |
| Puyuan, W | 1 |
| Wenwen, L | 1 |
| Zhi, S | 1 |
| Bondy, SC | 1 |
| Furuya, M | 1 |
| Miyaoka, T | 1 |
| Yasuda, H | 1 |
| Yamashita, S | 1 |
| Tanaka, I | 1 |
| Otsuka, S | 1 |
| Wake, R | 1 |
| Horiguchi, J | 1 |
| Noonan, CW | 1 |
| Reif, JS | 1 |
| Burch, JB | 1 |
| Ichinose, TY | 1 |
| Yost, MG | 1 |
| Magnusson, K | 1 |
| Montilla-López, P | 1 |
| Muñoz-Agueda, MC | 1 |
| Feijóo López, M | 1 |
| Muñoz-Castañeda, JR | 1 |
| Bujalance-Arenas, I | 1 |
| Túnez-Fiñana, I | 1 |
| Long, CO | 1 |
| Dougherty, J | 1 |
| Yu, CX | 1 |
| Cutrera, RA | 1 |
| Castillo Thea, V | 1 |
| Pérez Lloret, S | 1 |
| Riccio, P | 1 |
| Caccuri, RL | 1 |
| Brusco, LL | 1 |
| Bryant-Thomas, T | 2 |
| Pacheco Quinto, J | 1 |
| Henry, TL | 1 |
| Poeggeler, B | 4 |
| Herbert, D | 1 |
| Cruz-Sanchez, F | 1 |
| Chyan, YJ | 4 |
| Smith, MA | 3 |
| Shoji, M | 1 |
| Abe, K | 1 |
| Leone, A | 1 |
| Grundke-Ikbal, I | 1 |
| Wilson, GL | 2 |
| Ghiso, J | 5 |
| Williams, C | 1 |
| Refolo, LM | 1 |
| Pappolla, MA | 6 |
| Chain, DG | 1 |
| Neria, E | 1 |
| Zhou, JN | 3 |
| Liu, RY | 3 |
| Kamphorst, W | 1 |
| Hofman, MA | 2 |
| Swaab, DF | 7 |
| Olivieri, G | 4 |
| Otten, U | 1 |
| Meier, F | 3 |
| Baysang, G | 2 |
| Dimitriades-Schmutz, B | 1 |
| Müller-Spahn, F | 4 |
| Savaskan, E | 5 |
| Asayama, K | 1 |
| Yamadera, H | 1 |
| Ito, T | 1 |
| Suzuki, H | 1 |
| Kudo, Y | 1 |
| Endo, S | 1 |
| Abbott, A | 1 |
| Singer, C | 1 |
| Tractenberg, RE | 1 |
| Kaye, J | 1 |
| Schafer, K | 1 |
| Gamst, A | 1 |
| Grundman, M | 1 |
| Thomas, R | 1 |
| Thal, LJ | 1 |
| Wu, YH | 4 |
| Feenstra, MG | 1 |
| Toranõ, JS | 1 |
| Van Kan, HJ | 1 |
| Fischer, DF | 2 |
| Ravid, R | 2 |
| Smith, IF | 1 |
| Boyle, JP | 1 |
| Green, KN | 1 |
| Pearson, HA | 1 |
| Peers, C | 1 |
| Wang, YP | 1 |
| Li, XT | 1 |
| Liu, SJ | 2 |
| Zhou, XW | 1 |
| Wang, DL | 1 |
| Cao, FY | 1 |
| Mahlberg, R | 1 |
| Kunz, D | 1 |
| Sutej, I | 1 |
| Kühl, KP | 1 |
| Hellweg, R | 1 |
| Feng, Z | 5 |
| Chang, Y | 2 |
| Cheng, Y | 3 |
| Zhang, BL | 1 |
| Qu, ZW | 1 |
| Qin, C | 2 |
| Zhang, JT | 5 |
| Han, L | 1 |
| Zhou, ZT | 1 |
| Srinivasan, V | 2 |
| Pandi-Perumal, SR | 2 |
| Maestroni, GJ | 1 |
| Esquifino, AI | 1 |
| Hardeland, R | 1 |
| Wang, ZF | 1 |
| Lahiri, DK | 1 |
| Chen, DM | 1 |
| Lahiri, P | 1 |
| Bondy, S | 1 |
| Greig, NH | 1 |
| Zhang, QZ | 1 |
| Craig, D | 1 |
| Hart, DJ | 1 |
| Passmore, AP | 1 |
| Eeles, EM | 1 |
| Stephens, M | 1 |
| Benedict, C | 1 |
| Beaverstock, J | 1 |
| Gupta, M | 1 |
| Page, M | 1 |
| Reis, K | 1 |
| Land, T | 1 |
| Wang, S | 1 |
| Zhu, L | 1 |
| Liu, R | 1 |
| Kato, M | 1 |
| Kinoshita, H | 1 |
| Enokita, M | 1 |
| Hori, Y | 1 |
| Hashimoto, T | 1 |
| Iwatsubo, T | 1 |
| Toyo'oka, T | 1 |
| Burr, RL | 1 |
| Hubbard, EM | 1 |
| Luxenberg, JS | 1 |
| Mastick, J | 1 |
| Cooper, BA | 1 |
| Zhang, YC | 1 |
| Chatterjie, N | 1 |
| Grundke-Iqbal, I | 1 |
| Iqbal, K | 1 |
| Siwicka, A | 1 |
| Moleda, Z | 1 |
| Wojtasiewicz, K | 1 |
| Zawadzka, A | 1 |
| Maurin, JK | 1 |
| Panasiewicz, M | 1 |
| Pacuszka, T | 1 |
| Czarnocki, Z | 1 |
| Anderson, KN | 1 |
| Jamieson, S | 1 |
| Graham, AJ | 1 |
| Shneerson, JM | 1 |
| Sharer, J | 1 |
| Sandyk, R | 2 |
| Mishima, K | 2 |
| Okawa, M | 2 |
| Hishikawa, Y | 2 |
| Hozumi, S | 1 |
| Hori, H | 1 |
| Takahashi, K | 1 |
| Uchida, K | 2 |
| Okamoto, N | 2 |
| Ohara, K | 1 |
| Morita, Y | 2 |
| Stoll, S | 1 |
| Müller, WE | 1 |
| Sos, M | 1 |
| Omar, RA | 1 |
| Bick, RJ | 1 |
| Hickson-Bick, DL | 1 |
| Efthimiopoulos, S | 1 |
| Robakis, NK | 2 |
| van Rensburg, SJ | 1 |
| Daniels, WM | 1 |
| Potocnik, FC | 1 |
| van Zyl, JM | 1 |
| Taljaard, JJ | 1 |
| Emsley, RA | 1 |
| Pappolla, M | 1 |
| Bozner, P | 2 |
| Soto, C | 1 |
| Shao, H | 2 |
| Zagorski, M | 1 |
| Frangione, B | 3 |
| Jean-Louis, G | 1 |
| Zizi, F | 1 |
| von Gizycki, H | 1 |
| Taub, H | 1 |
| Márquez, M | 1 |
| van Heerikhuize, J | 1 |
| Tozawa, T | 1 |
| Satoh, K | 1 |
| Matsumoto, Y | 1 |
| Ohashi, Y | 1 |
| Iyo, M | 1 |
| Mori, N | 1 |
| Qi, WB | 1 |
| Kumar, AM | 1 |
| Tims, F | 1 |
| Cruess, DG | 1 |
| Mintzer, MJ | 1 |
| Ironson, G | 1 |
| Loewenstein, D | 1 |
| Cattan, R | 1 |
| Fernandez, JB | 1 |
| Eisdorfer, C | 1 |
| Kumar, M | 1 |
| LeDoux, SP | 1 |
| Bachurin, S | 1 |
| Oxenkrug, G | 1 |
| Lermontova, N | 1 |
| Afanasiev, A | 1 |
| Beznosko, B | 1 |
| Vankin, G | 1 |
| Shevtzova, E | 1 |
| Mukhina, T | 1 |
| Serkova, T | 1 |
| Cabrera, J | 1 |
| Sainz, RM | 1 |
| Mayo, JC | 1 |
| Eagle, C | 1 |
| Wilson, G | 1 |
| Ferrari, E | 1 |
| Arcaini, A | 1 |
| Gornati, R | 1 |
| Pelanconi, L | 1 |
| Cravello, L | 1 |
| Fioravanti, M | 1 |
| Solerte, SB | 1 |
| Magri, F | 1 |
| Clapp-Lilly, KL | 2 |
| Duffy, LK | 2 |
| Raghavendra, V | 1 |
| Kulkarni, SK | 1 |
| Harris, PL | 1 |
| Brydon, L | 2 |
| Kräuchi, K | 1 |
| Wirz-Justice, A | 2 |
| Andorn, AC | 1 |
| Luboshitzky, R | 1 |
| Shen-Orr, Z | 1 |
| Tzischichinsky, O | 1 |
| Maldonado, M | 1 |
| Herer, P | 1 |
| Lavie, P | 1 |
| Lack, B | 1 |
| Daya, S | 1 |
| Nyokong, T | 1 |
| Van Nostrand, WE | 1 |
| Melchor, JP | 1 |
| Hess, C | 1 |
| Ly, C | 1 |
| Brockhaus, M | 1 |
| Miravalle, L | 1 |
| Zagorski, MG | 1 |
| Wisniewski, T | 1 |
| Vidal, R | 1 |
| Ozcankaya, R | 1 |
| Olde Rikkert, MG | 1 |
| Rigaud, AS | 1 |
| Liberczuk, C | 1 |
| Skene, DJ | 1 |
| Vivien-Roels, B | 1 |
| Sparks, DL | 1 |
| Hunsaker, JC | 1 |
| Pévet, P | 1 |
| Ravid, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mirtazapine for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled Study[NCT01867775] | Phase 3 | 30 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| A Randomized Placebo-controlled Trial Evaluating the Effect of Melatonin on Sleep Quality in Patients With Dementia[NCT03066518] | Phase 4 | 40 participants (Actual) | Interventional | 2016-01-15 | Completed | ||
| Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients.[NCT00706186] | Phase 4 | 4 participants (Actual) | Interventional | Terminated (stopped due to Withdrawn by Investigator, protocol in revision) | |||
| [NCT00000171] | Phase 3 | 0 participants | Interventional | Completed | |||
| A Double-blind, Randomized Pilot Study to Evaluate the Effects of Galantamine and Donepezil on Sleep and Attention and Gastrointestinal (GI) Tolerance in Patients With Mild to Moderate Alzheimer's Disease (AD)[NCT00035204] | Phase 4 | 63 participants (Actual) | Interventional | Completed | |||
| A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor[NCT00940589] | Phase 2 | 73 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects[NCT00325728] | Phase 2 | 74 participants (Actual) | Interventional | 2006-03-21 | Completed | ||
| The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients[NCT00480870] | Phase 4 | 65 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Modafinil Treatment for Sleep/Wake Disturbances in Older Adults[NCT00626210] | Phase 4 | 2 participants (Actual) | Interventional | 2008-02-29 | Terminated | ||
| Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study[NCT00814502] | 20 participants (Actual) | Interventional | 2008-12-31 | Completed | |||
| Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial.[NCT02267057] | Phase 4 | 163 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Trazodone for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study[NCT01142258] | Phase 3 | 40 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease[NCT02750306] | Phase 3 | 285 participants (Actual) | Interventional | 2016-05-23 | Completed | ||
| A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild t[NCT01266525] | Phase 2 | 291 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Placebo-Controlled[NCT01548287] | Phase 2 | 164 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Prevalence of Epilepsy and Sleep Wake Disorders in Alzheimer Disease[NCT03617497] | 78 participants (Actual) | Interventional | 2020-12-01 | Active, not recruiting | |||
| Use of Melatonin for Prevention of POCD After TURP Surgery Under Spinal Anesthesia for Elderly Patients[NCT03966950] | 104 participants (Anticipated) | Interventional | 2017-06-26 | Recruiting | |||
| A Pilot, Open-label Study to Evaluate the Effects of a Prostate Health Formulation on Scores Attained From the International Prostate Symptom Score (I-PSS) Questionnaire Among Overall Healthy Male Participants Who Report Lower Urinary Tract Complaints[NCT02886832] | 30 participants (Anticipated) | Interventional | 2016-09-21 | Completed | |||
| Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2021-05-31 | Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study) | ||
| Narcolepsy Protect Against Alzheimer's Disease? Protective Role of Low Rates of Orexin on the Occurrence of Intracerebral Amyloid Deposits Characteristic of the Alzheimer's Disease: A Pilot Study[NCT03378453] | 38 participants (Actual) | Interventional | 2016-04-07 | Completed | |||
| Sleep and Circadian Regulation in Diabetic Retinopathy: The Role of Intrinsically Photosensitive Retinal Ganglion Cells and Melatonin Supplementation[NCT04547439] | Phase 2 | 36 participants (Anticipated) | Interventional | 2021-02-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) is a cognitive testing instrument used in clinical trials. It consists of 11 tasks measuring the disturbances of memory, language, praxis, attention, and other cognitive abilities that are often referred to as the core symptoms of AD. The test comprises 11 items summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. A negative change indicates an improvement from baseline. ADAS-cog was measured at base line and at end of treatment after 24 weeks. (NCT00940589)
Timeframe: 24 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Circadin | 0.45 |
| Placebo | 0.19 |
Instrumental Activities of Daily Living (iADL). The scale rates activities that represent key life tasks that people need to manage. These tasks are valuable for evaluating persons with early-stage disease, both to assess the level of disease and to determine the person's ability to care for himself or herself. Scores of 0 or 1 are given to every task (Bathing, Dressing, Tolieting, transferring, Continence and Feeding) to a total score of 6. , while 0 represents a patient who is very dependent and 6 represents patient who is independent. iADL was measured at base line and at end of treatment after 24 weeks. (NCT00940589)
Timeframe: 24 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Circadin | 0.77 |
| Placebo | 1.62 |
The Mini Mental State Examination (MMSE) is a brief assessment instrument used to assess cognitive function in elderly patients. The MMSE can be used to screen for cognitive impairment and as a measurement of cognition over time and with pharmacologic treatment. The instrument is divided into 2 sections. The first section measures orientation, memory, and attention: the maximum score is 21. The second section tests the ability of the patient to name objects, follow verbal and written commands, write a sentence, and copy figures: the maximum score is 9. The scoring range for the MMSE is 0-30. Higher score represents better performance. MMSE was measured at base line and at end of treatment after 24 weeks. (NCT00940589)
Timeframe: 24 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Circadin | -0.3 |
| Placebo | -1.9 |
(NCT00626210)
Timeframe: 1 month
| Intervention | hours (Median) |
|---|---|
| Modafinil | 9.5 |
"Sleep efficiency during the down interval. The down interval signifies the period of time (in minutes) at night when subjects are in bed and trying to sleep. Sleep efficiency is calculated as (100*sleep minutes)/[time interval from sleep onset (as defined by the sleep latency) to sleep offset (the end of the last sleep episode in the Down interval)].~The time period was different for each patient, it was their duration of hospitalization. The first 48 hours patients were not on the study drug, so the reported least squares mean is an estimate of the mean for the subsequent time period where the patients received different therapies. These means are corrected for differences that might have existed during the first 48 hours. The results would be similar to the results attained from considering the mean during the first 48 hours as a baseline covariate in an Analysis of Covariance, but would be more robust to missing data." (NCT00814502)
Timeframe: Post-intervention, up to 3 weeks
| Intervention | percentage of sleep (see above) (Least Squares Mean) |
|---|---|
| Zolpidem CR | 75.93 |
| Placebo | 75.30 |
"Total sleep minutes during the down period. The down interval signifies the period of time (in minutes) at night when subjects are in bed and trying to sleep.~The time period was different for each patient, it was their duration of hospitalization. The first 48 hours patients were not on the study drug, so the reported least squares mean is an estimate of the mean for the subsequent time period where the patients received different therapies. These means are corrected for differences that might have existed during the first 48 hours. The results would be similar to the results attained from considering the mean during the first 48 hours as a baseline covariate in an Analysis of Covariance, but would be more robust to missing data." (NCT00814502)
Timeframe: post-intervention, up to 3 weeks
| Intervention | sleep minutes (Least Squares Mean) |
|---|---|
| Zolpidem CR | 443.71 |
| Placebo | 422.49 |
"Rating Scale for Aggressive Behavior in the Elderly (RAGE, 0-61); higher is worse.~Disruptive Behavior Rating Scales (DBRS, 0-105); higher is worse.~Neuropsychiatric Inventory (NPI, 0-144) - measures 12 different domains of neuropsychiatric symptoms such as delusions, hallucinations, anxiety, depression, apathy, etc.; higher is worse.~Montgomery-Asberg Depression Rating Scale (MADRS, 0-90); higher is worse.~Mini-mental state examination (MMSE, 0-30); higher is better.~The time period was different for each patient, it was their duration of hospitalization. The first 48 hours patients were not on the study drug, so the reported least squares mean is an estimate of the mean for the subsequent time period where the patients received different therapies. These means are corrected for differences that might have existed during the first 48 hours. The results would be similar to the results attained from considering the mean during the firs" (NCT00814502)
Timeframe: post-intervention, up to 3 weeks
| Intervention | units on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| NPI Total Score | RAGE Total Score | DBRS Total Score | MMSE Total Score | MADRS Total Score | |
| Placebo | 18.64 | 5.82 | 22.47 | 21.57 | 22.56 |
| Zolpidem CR | 18.00 | 1.40 | 22.64 | 24.45 | 22.96 |
TST was measured at Baseline and at Week 4 in a sleep laboratory by polysomnography, during an 8-hour recording period beginning at participants' habitual bedtime. (NCT02750306)
Timeframe: Baseline and Week 4
| Intervention | Minutes (Least Squares Mean) |
|---|---|
| Suvorexant | 73.4 |
| Placebo | 45.2 |
WASO was measured at Baseline and at Week 4 in a sleep laboratory by polysomnography during an 8-hour recording period beginning at participants' habitual bedtime. (NCT02750306)
Timeframe: Baseline and Week 4
| Intervention | Minutes (Least Squares Mean) |
|---|---|
| Suvorexant | -45.0 |
| Placebo | -29.4 |
An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. (NCT02750306)
Timeframe: Up to 4 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Suvorexant | 0.7 |
| Placebo | 0.7 |
An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. (NCT02750306)
Timeframe: Up to 6 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Suvorexant | 22.5 |
| Placebo | 16.1 |
Change from baseline in latency of persistent sleep after 4 weeks of treatment, based on participants with valid baseline and week 4 actigraphy data (NCT01548287)
Timeframe: Baseline and Week 4.
| Intervention | Minutes (Least Squares Mean) |
|---|---|
| AZD5213 Dose A | 1.77 |
| AZD5213 Dose B | 9.84 |
| AZD5213 Dose C | -6.85 |
| Placebo | 2.70 |
(NCT01548287)
Timeframe: Baseline and Week 4.
| Intervention | Rank transformed duration (minutes) (Least Squares Mean) |
|---|---|
| AZD5213 Dose A | -2.23 |
| AZD5213 Dose B | 14.48 |
| AZD5213 Dose C | -5.84 |
| Placebo | -5.68 |
Change from baseline in night total sleep time after 4 weeks of treatment: assessed if valid baseline and week 4 actigraphy data (NCT01548287)
Timeframe: Baseline and Week 4.
| Intervention | Minutes (Least Squares Mean) |
|---|---|
| AZD5213 Dose A | 7.07 |
| AZD5213 Dose B | -12.42 |
| AZD5213 Dose C | -18.97 |
| Placebo | -7.51 |
Change from baseline in sleep efficiency after 4 weeks of treatment, based on participants with valid baseline and week 4 actigraphy data (NCT01548287)
Timeframe: Baseline and Week 4.
| Intervention | % (efficiency=% of time asleep) (Least Squares Mean) |
|---|---|
| AZD5213 Dose A | -0.05 |
| AZD5213 Dose B | -3.20 |
| AZD5213 Dose C | -1.92 |
| Placebo | -1.83 |
(NCT01548287)
Timeframe: Baseline and Week 4.
| Intervention | % change (Least Squares Mean) |
|---|---|
| AZD5213 Dose A | 0.08 |
| AZD5213 Dose B | -1.51 |
| AZD5213 Dose C | -2.82 |
| Placebo | 0.96 |
Total sleep time (TST) is defined as the total time in minutes, that subjects were determined to be in a sleep state by polysomnography (PSG) measurement. (NCT01548287)
Timeframe: Baseline and Week 4.
| Intervention | Minutes (Least Squares Mean) |
|---|---|
| AZD5213 Dose A | 6.43 |
| AZD5213 Dose B | -12.53 |
| AZD5213 Dose C | -19.41 |
| Placebo | 14.48 |
91 reviews available for melatonin and Alzheimer Disease
| Article | Year |
|---|---|
A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cell Line, Tumor; Coumaric Acids; H | 2021 |
Impact of Pharmacotherapy on Insomnia in Patients with Alzheimer's Disease.
Topics: Alzheimer Disease; Humans; Melatonin; Sleep; Sleep Initiation and Maintenance Disorders; Sleep Wake | 2021 |
[Sleep disorders in patients with a neurocognitive disorder].
Topics: Alzheimer Disease; Chronobiology Disorders; Humans; Melatonin; REM Sleep Behavior Disorder; Restless | 2022 |
Melatonin hormone as a therapeutic weapon against neurodegenerative diseases.
Topics: Alzheimer Disease; Animals; Antioxidants; Humans; Melatonin; Neurodegenerative Diseases; Neuroprotec | 2021 |
A Growing Link between Circadian Rhythms, Type 2 Diabetes Mellitus and Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Circadian Rhythm; Diabetes Mellitus, Type 2; Humans; Melatonin | 2022 |
Role of melatonin in Alzheimer's disease: From preclinical studies to novel melatonin-based therapies.
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Humans; Melatonin; Neuronal Plasticity; Sleep | 2022 |
The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Antioxidants; Diabetes Mellitus, Type 2; Humans; Inflam | 2022 |
The Dose and Duration-dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer's Dementia: A Network Meta- Analysis of Randomized Placebo-Controlled Trials.
Topics: Alzheimer Disease; Cognition; Humans; Melatonin; Network Meta-Analysis; Randomized Controlled Trials | 2022 |
The Involvement of Melatonin and Tasimelteon against Alzheimer's Disease.
Topics: Alzheimer Disease; Humans; Melatonin; Neurodegenerative Diseases; Sleep Initiation and Maintenance D | 2023 |
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
Topics: Alzheimer Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti- | 2022 |
Importance of Bmal1 in Alzheimer's disease and associated aging-related diseases: Mechanisms and interventions.
Topics: Adiponectin; Aging; Alzheimer Disease; ARNTL Transcription Factors; Diabetes Mellitus, Type 2; Human | 2022 |
Effect and Mechanism of Exogenous Melatonin on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic Review and Meta-analysis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; Disease Models, Animal; Maze Learning; | 2022 |
Melatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress.
Topics: Aged; Alzheimer Disease; Antioxidants; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum St | 2023 |
Oxidative Stress and Aging as Risk Factors for Alzheimer's Disease and Parkinson's Disease: The Role of the Antioxidant Melatonin.
Topics: Aged; Aging; Alzheimer Disease; Antioxidants; Humans; Melatonin; Neurodegenerative Diseases; Oxidati | 2023 |
Brain washing and neural health: role of age, sleep, and the cerebrospinal fluid melatonin rhythm.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Glymphatic System; Humans; Melatoni | 2023 |
Melatonin as a Harmonizing Factor of Circadian Rhythms, Neuronal Cell Cycle and Neurogenesis: Additional Arguments for Its Therapeutic Use in Alzheimer's Disease.
Topics: Alzheimer Disease; Cell Cycle; Circadian Rhythm; Humans; Melatonin; Neurogenesis | 2023 |
Light, Water, and Melatonin: The Synergistic Regulation of Phase Separation in Dementia.
Topics: Adenosine; Adenosine Triphosphate; Alzheimer Disease; Humans; Melatonin; Water | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Gut Microbiome and Circadian Interactions with Platelets Across Human Diseases, including Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Cancer.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Gastrointestinal Microbiome; Humans; Melatonin; Ne | 2023 |
Role of Bmal1 and Gut Microbiota in Alzheimer's Disease and Parkinson's Disease Pathophysiology: The Probable Effect of Melatonin on Their Association.
Topics: Alzheimer Disease; Gastrointestinal Microbiome; Humans; Melatonin; Neurodegenerative Diseases; Parki | 2023 |
The location, physiology, pathology of hippocampus Melatonin MT
Topics: Alzheimer Disease; Hippocampus; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT | 2023 |
Alzheimer's disease pathogenesis: The role of disturbed sleep in attenuated brain plasticity and neurodegenerative processes.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cofilin 1; Cytokines; Disease Models, Animal; Hum | 2019 |
Antioxidants and Neuron-Astrocyte Interplay in Brain Physiology: Melatonin, a Neighbor to Rely on.
Topics: Alzheimer Disease; Animals; Antioxidants; Astrocytes; Brain; Brain Neoplasms; Cell Line, Tumor; Huma | 2021 |
Therapeutic potential of neurogenesis and melatonin regulation in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Circadian Rhythm; Cognitive Dysfunction; D | 2020 |
Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Circadian Rhythm; Dementia, Vascular; Hum | 2020 |
Decoding the Inter-Relationship between Sleep Disorders and Alzheimer's Disease Pathogenesis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloidogenic Proteins; Humans; Melatonin; Neurofibrillary | 2021 |
Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Autophagy; Autophagy | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyr | 2020 |
Melatonin regulates Aβ production/clearance balance and Aβ neurotoxicity: A potential therapeutic molecule for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Glymphatic System; Humans; Melatonin | 2020 |
Exploring the multifunctional role of melatonin in regulating autophagy and sleep to mitigate Alzheimer's disease neuropathology.
Topics: Alzheimer Disease; Autophagy; Circadian Rhythm; Humans; Melatonin; Sleep | 2021 |
Melatonin levels in the Alzheimer's disease continuum: a systematic review.
Topics: Alzheimer Disease; Biomarkers; Diagnosis, Differential; Humans; Melatonin | 2021 |
Deciphering the Interacting Mechanisms of Circadian Disruption and Alzheimer's Disease.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Circadian Rhythm; Gastrointestin | 2021 |
Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer's disease and insomnia: A systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Alzheimer Disease; Cognition Disorders; Humans; Melatonin; Randomized Controlled Trials as To | 2021 |
Regulation of Melatonin and Neurotransmission in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biogenic Monoamines; Disease Susceptibility; Humans; Melat | 2021 |
Melatonin and Sleep Disturbances in Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antioxidants; Circadian Rhythm; Humans; Melatonin; Sleep | 2021 |
Circadian Disruption Associated with Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloidogenic Proteins; Animals; Circadian Rhythm; Humans; Melatonin; Phototherap | 2017 |
[Melatonin as a molecular marker of age-related pathologies].
Topics: Age Factors; Alzheimer Disease; Biomarkers; Circadian Rhythm; Enterocytes; Humans; Melatonin; Mouth | 2017 |
The long-lived Octodon degus as a rodent drug discovery model for Alzheimer's and other age-related diseases.
Topics: Alzheimer Disease; Animals; Atherosclerosis; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug | 2018 |
Multi-Faceted Role of Melatonin in Neuroprotection and Amelioration of Tau Aggregates in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Humans; Melatonin; Neuroprotection; Protein Aggregates; Protein Aggregat | 2018 |
Melatonin in Synaptic Impairments of Alzheimer's Disease.
Topics: Alzheimer Disease; Brain; Humans; Melatonin; Receptors, Melatonin; Synapses | 2018 |
Protective roles of melatonin against the amyloid-dependent development of Alzheimer's disease: A critical review.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Humans; Me | 2018 |
Neuroendocrine-Metabolic Dysfunction and Sleep Disturbances in Neurodegenerative Disorders: Focus on Alzheimer's Disease and Melatonin.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognitive Dysfunction; Humans; Melatonin; | 2019 |
On the Etiopathogenesis and Pathophysiology of Alzheimer's Disease: A Comprehensive Theoretical Review.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Gonadal Steroid Hormones; Humans; Melatonin; Mitochondria; | 2019 |
The role of sleep deprivation and circadian rhythm disruption as risk factors of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Circadian Rhythm; Glymphatic System; Humans; Melatonin; Oxidative Stress | 2019 |
Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.
Topics: Alzheimer Disease; Animals; Brain; Circadian Rhythm; Humans; Melatonin; Molecular Targeted Therapy; | 2019 |
Pineal gland dysfunction in Alzheimer's disease: relationship with the immune-pineal axis, sleep disturbance, and neurogenesis.
Topics: Alzheimer Disease; Animals; Circadian Rhythm; Humans; Melatonin; Neurodegenerative Diseases; Neuroge | 2019 |
Melatonin in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Humans; Melatonin; Phosphorylation; tau Proteins | 2013 |
Pharmacotherapies for sleep disturbances in Alzheimer's disease.
Topics: Alzheimer Disease; Humans; Indenes; Melatonin; Randomized Controlled Trials as Topic; Sleep; Sleep W | 2014 |
Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Humans; Melatonin; Metabolic Networks and Pathways; Tryptophan | 2016 |
Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials.
Topics: Alzheimer Disease; Central Nervous System Depressants; Cognition; Cognition Disorders; Dementia; Dem | 2015 |
Sleep-related behaviors in Alzheimer's disease and dementia with Lewy bodies.
Topics: Alzheimer Disease; Animals; Behavior; Humans; Lewy Body Disease; Melatonin; Sleep; Sleep Wake Disord | 2015 |
Pharmacotherpy and Alzheimer's Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach.
Topics: Alzheimer Disease; Animals; Benzhydryl Compounds; Cognitive Dysfunction; Humans; Melatonin; Memantin | 2016 |
Brain metabolism as a modulator of autophagy in neurodegeneration.
Topics: Alzheimer Disease; Animals; Autophagy; Brain; Cholesterol; Ghrelin; Glucose; Glycogen; Homeostasis; | 2016 |
Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer's disease.
Topics: Alzheimer Disease; Double-Blind Method; Humans; Melatonin; Randomized Controlled Trials as Topic; Sl | 2017 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Humans; Indenes; Melatonin; Randomized Controlled Trials as Topic; Sleep; Sleep W | 2016 |
Sleep and Neurodegeneration: A Critical Appraisal.
Topics: Alzheimer Disease; Dementia; Humans; Lewy Body Disease; Melatonin; Multiple System Atrophy; Neurodeg | 2017 |
Mechanisms of Melatonin in Alleviating Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Humans; Melatonin; Neuroprotective Agents | 2017 |
Suprachiasmatic nucleus and melatonin: reciprocal interactions and clinical correlations.
Topics: Aging; Alzheimer Disease; Animals; Circadian Rhythm; Humans; Melatonin; Pineal Gland; Sleep Wake Dis | 2008 |
[Melatonina: old molecule, new medicament].
Topics: Administration, Oral; Age Factors; Aged; Alzheimer Disease; Animals; Antioxidants; Central Nervous S | 2008 |
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzo | 2010 |
Non-pharmacologic management of sleep disturbance in Alzheimer's disease.
Topics: Actigraphy; Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Cognitive Behavioral Therap | 2010 |
Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs?
Topics: Alzheimer Disease; Animals; Cholinergic Agents; Drug Therapy, Combination; Humans; Melatonin; Recept | 2010 |
[Melatonin and Alzheimer's disease].
Topics: Alzheimer Disease; Brain; Humans; Melatonin | 2010 |
Neuroinflammation and ageing: current theories and an overview of the data.
Topics: Aging; Alzheimer Disease; Apoptosis; Atherosclerosis; Biological Evolution; Brain; Cellular Senescen | 2011 |
[Melatonin: its role in the system of neurohumoral regulation in man. Part 2].
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Anticarcinogenic Agents; Blood Pressure; Cardiova | 2011 |
The use of chronobiotics in the resynchronization of the sleep/wake cycle. Therapeutical application in the early phases of Alzheimer's disease.
Topics: Alzheimer Disease; Circadian Rhythm; Cognitive Dysfunction; Female; Humans; Male; Melatonin; Sleep D | 2011 |
Relevance of the chronobiological and non-chronobiological actions of melatonin for enhancing therapeutic efficacy in neurodegenerative disorders.
Topics: Alzheimer Disease; Antioxidants; Encephalitis; Humans; Melatonin; Neurodegenerative Diseases; Pineal | 2011 |
Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin.
Topics: Alzheimer Disease; Animals; Humans; Melatonin | 2012 |
The senescence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Disease Models, Animal; Ho | 2012 |
Melatonin and mitochondrial dysfunction in the central nervous system.
Topics: Alzheimer Disease; Animals; Humans; Huntington Disease; Melatonin; Mitochondria; Parkinson Disease | 2013 |
[Melatonin agonist: a possible disease-modifying agent for Alzheimer's disease].
Topics: Alzheimer Disease; Animals; Humans; Melatonin; Mice | 2012 |
Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: focus on the role of hypocretin and melatonin.
Topics: Alzheimer Disease; Circadian Rhythm; Humans; Intracellular Signaling Peptides and Proteins; Melatoni | 2013 |
What's new in Alzheimer's disease?
Topics: Activities of Daily Living; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticholeste | 2003 |
Sleep disorders in Alzheimer's disease and other dementias.
Topics: Accidental Falls; Alzheimer Disease; Antipsychotic Agents; Body Temperature Regulation; Chronobiolog | 2004 |
The human pineal gland and melatonin in aging and Alzheimer's disease.
Topics: Aged; Aging; Alzheimer Disease; Circadian Rhythm; Humans; Melatonin; Phototherapy; Pineal Gland; Sup | 2005 |
Role of melatonin in neurodegenerative diseases.
Topics: Aging; Alzheimer Disease; Animals; Antioxidants; Brain Chemistry; Brain Injuries; Free Radical Scave | 2005 |
Melatonin and sleep in aging population.
Topics: Aged; Aging; Alzheimer Disease; Body Temperature Regulation; Female; Humans; Indenes; Indoles; Male; | 2005 |
Role of melatonin in Alzheimer-like neurodegeneration.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Humans; Melatonin; Neurofibrillary | 2006 |
Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases.
Topics: Aging; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Cell Physiological Phenomena; Cho | 2005 |
Beneficial effects of melatonin in experimental models of Alzheimer disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Cognition; Free Radical | 2006 |
Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Biological Clocks; Circadian Rhythm; Disease Progression; Humans; Melatoni | 2007 |
Tackling sundowning in a patient with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antipsychotic Agents; Behavior Therapy; Circadian Rhyt | 2008 |
Alzheimer's disease: improvement of visual memory and visuoconstructive performance by treatment with picotesla range magnetic fields.
Topics: Aged; Alzheimer Disease; Brain; Circadian Rhythm; Cognition; Electromagnetic Fields; Humans; Magneti | 1994 |
[Melatonin. Hormone or wonder drug?].
Topics: Adult; Aged; Aging; Alzheimer Disease; Animals; Circadian Rhythm; Depressive Disorder; Humans; Melat | 1996 |
The accelerated aging hypothesis of Parkinson's disease is not supported by the pattern of circadian melatonin secretion.
Topics: Aging; Alzheimer Disease; Circadian Rhythm; Dopamine; Humans; Melatonin; Middle Aged; Parkinson Dise | 1997 |
Suppression of oxygen toxicity by melatonin.
Topics: Alzheimer Disease; Animals; Antioxidants; Free Radical Scavengers; Humans; Melatonin | 1998 |
Music therapy increases serum melatonin levels in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Follow-Up Studies; Humans; Male; Melatonin; Music Therap | 1999 |
Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism.
Topics: Alzheimer Disease; Animals; Cell Death; Drug Evaluation, Preclinical; Free Radical Scavengers; Free | 1999 |
An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Free Radicals; Humans; Melatonin; N | 2000 |
Melatonin in elderly patients with insomnia. A systematic review.
Topics: Aged; Alzheimer Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; | 2001 |
The use of melatonin in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antioxidants; Circadian Rhythm; Clinical Trials as Topic; Humans; Melatonin | 2002 |
13 trials available for melatonin and Alzheimer Disease
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Melatonin effects on EEG activity during non-rapid eye movement sleep in mild-to-moderate Alzheimer´s disease: a pilot study.
Topics: Aged; Alzheimer Disease; Brain Waves; Central Nervous System Depressants; Cross-Over Studies; Electr | 2021 |
Dietary Melatonin Therapy Alleviates the Lamina Cribrosa Damages in Patients with Mild Cognitive Impairments: A Double-Blinded, Randomized Controlled Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; China; Cognitive Dysf | 2020 |
EEG coherence and power spectra during REM sleep related to melatonin intake in mild-to-moderate Alzheimer's disease: a pilot study.
Topics: Alzheimer Disease; Electroencephalography; Humans; Melatonin; Pilot Projects; Single-Blind Method; S | 2023 |
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Delayed-Action Pre | 2014 |
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Delayed-Action Pre | 2014 |
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Delayed-Action Pre | 2014 |
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Delayed-Action Pre | 2014 |
Low-Dose Atypical Antipsychotic Risperidone Improves the 5-Year Outcome in Alzheimer's Disease Patients with Sleep Disturbances.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Caregivers; Donepezil; Female; Hum | 2015 |
Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Central Nervous System Depressants; Circadian Rhythm; Double-Blind Method; | 2009 |
Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia.
Topics: Aged; Alzheimer Disease; Circadian Rhythm; Cognition; Double-Blind Method; Humans; Male; Melatonin; | 2003 |
A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antioxidants; Circadian Rhythm; Delayed-Action Preparations; Double-Blind M | 2003 |
A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antioxidants; Circadian Rhythm; Delayed-Action Preparations; Double-Blind M | 2003 |
A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antioxidants; Circadian Rhythm; Delayed-Action Preparations; Double-Blind M | 2003 |
A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antioxidants; Circadian Rhythm; Delayed-Action Preparations; Double-Blind M | 2003 |
Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antioxidants; Circadian Rhythm; Female; Humans; Linear M | 2008 |
Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arousal; Circadian Rhythm; Dementia, Multi-Infarct; Fema | 1994 |
[Melatonin. Hormone or wonder drug?].
Topics: Adult; Aged; Aging; Alzheimer Disease; Animals; Circadian Rhythm; Depressive Disorder; Humans; Melat | 1996 |
Music therapy increases serum melatonin levels in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Follow-Up Studies; Humans; Male; Melatonin; Music Therap | 1999 |
176 other studies available for melatonin and Alzheimer Disease
| Article | Year |
|---|---|
Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Blood-Brain Barrier; Cholinesterase | 2006 |
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Humans; Plaque, Amyloid; Protein Structu | 2007 |
Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Calc | 2010 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel | 2011 |
Benzenediol-berberine hybrids: multifunctional agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Berberine; Cholinesterase I | 2011 |
New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2012 |
Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholines | 2012 |
Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Apoptosis; Carbamates; Chickens; Cholinesterase Inhibitors | 2012 |
New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Blood-Brain Barrier; Cell Line; Cholinesterase Inhibitors; Humans; | 2014 |
Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer's disease therapy.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Curcumin; | 2014 |
New multifunctional melatonin-derived benzylpyridinium bromides with potent cholinergic, antioxidant, and neuroprotective properties as innovative drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Cell Line, Tumor; Cholinesterase Inhibitors; Cholinesterases; Dose- | 2015 |
Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain B | 2016 |
Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell S | 2016 |
The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators.
Topics: Alzheimer Disease; Antioxidants; Cell Death; Cell Survival; Cholinesterase Inhibitors; Cholinesteras | 2016 |
Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Apigenin; Benzaldehy | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don | 2017 |
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Binding Sites; Blood-Bra | 2017 |
Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzylamines; Blood-Retinal Barrier; | 2017 |
Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Proliferation; Drug Des | 2018 |
Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Donepezil; E | 2018 |
New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H
Topics: Alzheimer Disease; Animals; Calcium Channel Blockers; Cholinesterase Inhibitors; Humans; Memory Diso | 2019 |
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
Topics: Alzheimer Disease; Animals; Catalytic Domain; Cell Line, Transformed; Coumaric Acids; Histone Deacet | 2021 |
Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Cyclic Nucleotide Phosphodiesterases, Type 2; Dose-Response Relatio | 2021 |
Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cognition; Melatonin; Mice; Mitophagy; P | 2021 |
Dynamic white lighting to aid sleep and vision for persons living with dementia using off-the-shelf LED strips.
Topics: Aged; Alzheimer Disease; Circadian Clocks; Humans; Light; Lighting; Melatonin; Phototherapy; Sleep W | 2021 |
Bioinformatics and Network Pharmacology Identify the Therapeutic Role and Potential Mechanism of Melatonin in AD and Rosacea.
Topics: Alzheimer Disease; Animals; Computational Biology; Female; Human Umbilical Vein Endothelial Cells; H | 2021 |
Activation of melatonin receptor 1 by CRISPR-Cas9 activator ameliorates cognitive deficits in an Alzheimer's disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; CRISPR-Cas Systems; Disease Models, An | 2022 |
Melatonin and zinc supplements with physical and mental activities subside neurodegeneration and hepatorenal injury induced by aluminum chloride in rats: Inclusion of GSK-3β-Wnt/β-catenin signaling pathway.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Animals; beta Catenin; Dietary Supplemen | 2022 |
Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cyclin-Dependent Kinase 5; Melatonin; Mice; MicroRNAs; Neurofibrillary T | 2022 |
Astrocyte Dysregulation and Calcium Ion Imbalance May Link the Development of Osteoporosis and Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Astrocytes; Calcium; Humans; Ions; Melatonin; Osteoporosis | 2022 |
Gut Microbiota Dysbiosis Induced by Decreasing Endogenous Melatonin Mediates the Pathogenesis of Alzheimer's Disease and Obesity.
Topics: Alzheimer Disease; Animals; Dysbiosis; Gastrointestinal Microbiome; Inflammation; Melatonin; Mice; O | 2022 |
Melatonin Attenuates Methamphetamine-Induced Alteration of Amyloid β Precursor Protein Cleaving Enzyme Expressions via Melatonin Receptor in Human Neuroblastoma Cells.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Pr | 2022 |
Microglial polarization differentially affects neuronal vulnerability to the β-amyloid protein: Modulation by melatonin.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents; Humans; Melatonin; Microglia; Ne | 2022 |
Novel melatonin-trientine conjugate as potential therapeutic agents for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Chelating A | 2022 |
Electroacupuncture ameliorates cerebrovascular impairment in Alzheimer's disease mice via melatonin signaling.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Electroacupuncture; Melatonin; Mice; Mice, Trans | 2023 |
Electroacupuncture ameliorates cerebrovascular impairment in Alzheimer's disease mice via melatonin signaling.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Electroacupuncture; Melatonin; Mice; Mice, Trans | 2023 |
Electroacupuncture ameliorates cerebrovascular impairment in Alzheimer's disease mice via melatonin signaling.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Electroacupuncture; Melatonin; Mice; Mice, Trans | 2023 |
Electroacupuncture ameliorates cerebrovascular impairment in Alzheimer's disease mice via melatonin signaling.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Electroacupuncture; Melatonin; Mice; Mice, Trans | 2023 |
Electroacupuncture ameliorates cerebrovascular impairment in Alzheimer's disease mice via melatonin signaling.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Electroacupuncture; Melatonin; Mice; Mice, Trans | 2023 |
Electroacupuncture ameliorates cerebrovascular impairment in Alzheimer's disease mice via melatonin signaling.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Electroacupuncture; Melatonin; Mice; Mice, Trans | 2023 |
Electroacupuncture ameliorates cerebrovascular impairment in Alzheimer's disease mice via melatonin signaling.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Electroacupuncture; Melatonin; Mice; Mice, Trans | 2023 |
Electroacupuncture ameliorates cerebrovascular impairment in Alzheimer's disease mice via melatonin signaling.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Electroacupuncture; Melatonin; Mice; Mice, Trans | 2023 |
Electroacupuncture ameliorates cerebrovascular impairment in Alzheimer's disease mice via melatonin signaling.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Electroacupuncture; Melatonin; Mice; Mice, Trans | 2023 |
Dual functional antioxidant and butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of novel melatonin-alkylbenzylamine hybrids.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholin | 2023 |
Regulatory role of melatonin in Notch1 signaling pathway in cerebral cortex of Aβ
Topics: Alzheimer Disease; Animals; Cerebral Cortex; Melatonin; Neurodegenerative Diseases; Peptide Fragment | 2023 |
Multi-Targeting Intranasal Nanoformulation as a Therapeutic for Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Insulins; | 2023 |
Changes in Reported Dietary Supplement Use in Cognitively Normal National Alzheimer's Coordinating Center Participants Aged 55 and Older From 2015 to 2019.
Topics: Aged; Alzheimer Disease; Biotin; Cross-Sectional Studies; Dietary Supplements; Humans; Melatonin; Vi | 2023 |
The role of melatonin in amyloid beta-induced inflammation mediated by inflammasome signaling in neuronal cell lines.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Caspase 1; Cell Line; Cytokines; Humans; Inflammasomes; In | 2023 |
Multi-target 1,4-dihydropyridines showing calcium channel blockade and antioxidant capacity for Alzheimer's disease therapy.
Topics: Alzheimer Disease; Antioxidants; Calcium; Calcium Channel Blockers; Calcium Channels; Dihydropyridin | 2019 |
Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-predominant mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cholineste | 2019 |
Evening melatonin timing secretion in real life conditions in patients with Alzheimer disease of mild to moderate severity.
Topics: Alzheimer Disease; Circadian Rhythm; Female; Humans; Male; Melatonin; Middle Aged; Saliva; Sleep; Su | 2019 |
Melatonin interacts with repeat domain of Tau to mediate disaggregation of paired helical filaments.
Topics: Alzheimer Disease; Amino Acid Sequence; Humans; Magnetic Resonance Spectroscopy; Melatonin; Neurons; | 2020 |
Melatonin attenuates streptozotocin-induced Alzheimer-like features in hyperglycemic rats.
Topics: Alzheimer Disease; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Disease Mo | 2020 |
Melatonin and its metabolite N(1)-acetyl-N(1)-formyl-5-methoxykynuramine improve learning and memory impairment related to Alzheimer's disease in rats.
Topics: Alzheimer Disease; Animals; Antioxidants; Behavior, Animal; Brain; Glutathione Peroxidase; Kynuramin | 2020 |
Near-Infrared Responsive Dopamine/Melatonin-Derived Nanocomposites Abrogating in Situ Amyloid β Nucleation, Propagation, and Ameliorate Neuronal Functions.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Brain; Brain Chemistry; Cell Line, Tumor | 2020 |
Melatonin directly binds and inhibits death-associated protein kinase 1 function in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Death-Associated Protein Kinases; Gene Expression Regulation, Enz | 2020 |
The effects of melatonin, serotonin, tryptophan and NAS on the biophysical properties of DPPC monolayers.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Alzheimer Disease; Humans; Melatonin; Membrane Fluidity; Membran | 2020 |
Therapeutic effects of melatonin-treated bone marrow mesenchymal stem cells (BMSC) in a rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Apoptosis; Avoidance Learning; Disease Models, Animal; Mal | 2020 |
Long-term oral melatonin alleviates memory deficits, reduces amyloid-β deposition associated with downregulation of BACE1 and mitophagy in APP/PS1 transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2020 |
Screening of sleep assisting drug candidates with a Drosophila model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Circadian Rhythm; Disease Models, Animal; Drosoph | 2020 |
Melatonin Induction of APP Intracellular Domain 50 SUMOylation Alleviates AD through Enhanced Transcriptional Activation and Aβ Degradation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; CREB-Binding Prot | 2021 |
Melatonin controversies, an update.
Topics: Alzheimer Disease; Animals; Antioxidants; COVID-19 Drug Treatment; Humans; Melatonin | 2021 |
Effects of melatonin and resveratrol on recognition memory and passive avoidance performance in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Behavior, Animal; Disease Models, Animal; Male; Mela | 2021 |
Melatonin Attenuates High Glucose-Induced Changes in Beta Amyloid Precursor Protein Processing in Human Neuroblastoma Cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2022 |
Positive effect of timed blue-enriched white light on sleep and cognition in patients with mild and moderate Alzheimer's disease.
Topics: Actigraphy; Affect; Aged; Aged, 80 and over; Alzheimer Disease; Behavior; Circadian Rhythm; Cognitio | 2021 |
Melatonin protects against methamphetamine-induced Alzheimer's disease-like pathological changes in rat hippocampus.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Central Nervous System Stimulants; | 2021 |
Norepinephrine May Oppose Other Neuromodulators to Impact Alzheimer's Disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain Chem | 2021 |
Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer's Disease but Are Not Correlated with Cognitive Decline.
Topics: Aged; Alzheimer Disease; Biomarkers; Cognitive Dysfunction; Cross-Sectional Studies; Female; Humans; | 2021 |
Melatonin binds with high affinity and specificity to beta-amyloid: LC-MS provides insight into Alzheimer's disease treatment.
Topics: Alzheimer Disease; Chromatography, Liquid; Humans; Melatonin; Plaque, Amyloid; Tandem Mass Spectrome | 2021 |
Neuroprotective effect of melatonin on soluble Aβ
Topics: Adaptor Proteins, Signal Transducing; Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; | 2017 |
Melatonin enhances neural stem cell differentiation and engraftment by increasing mitochondrial function.
Topics: Alzheimer Disease; Animals; Antigens, Differentiation; Cell Differentiation; Graft Survival; Male; M | 2017 |
Melatonin ameliorates anxiety and depression-like behaviors and modulates proteomic changes in triple transgenic mice of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Anxiety; Depression; Disease Models, Animal; Glutathione Transferase; Hi | 2017 |
Melatonin ameliorates Aβ
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Behavior, Animal; Cognition Disorders; | 2018 |
Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Biomarkers; Female; Genotype; Homocys | 2018 |
Melatonin receptor type 1A gene linked to Alzheimer's disease in old age.
Topics: Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Brain; | 2018 |
Mitochondrial biogenesis mediated by melatonin in an APPswe/PS1dE9 transgenic mice model.
Topics: Alzheimer Disease; Animals; Antioxidants; Brain; Disease Models, Animal; Male; Maze Learning; Melato | 2018 |
Antidepressant agomelatine attenuates behavioral deficits and concomitant pathology observed in streptozotocin-induced model of Alzheimer's disease in male rats.
Topics: Acetamides; Alzheimer Disease; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Disease Mo | 2019 |
Effects of melatonin on expressions of β-amyloid protein and S100β in rats with senile dementia.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Female; Hippocampus; Male; Melatonin; Rats; Rats, | 2018 |
Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Chromones | 2019 |
Protective effects of melatonin on mitochondrial biogenesis and mitochondrial structure and function in the HEK293-APPswe cell model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Aspartic Ac | 2019 |
Melatonin-pretreated adipose-derived mesenchymal stem cells efficeintly improved learning, memory, and cognition in an animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Avoidance Learning; Cognition; Dise | 2019 |
Effect of melatonin on Aβ42 induced changes in the mitochondrial function related to Alzheimer's disease in Drosophila melanogaster.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Antioxidants; Dise | 2019 |
Disease-modified glycogen synthase kinase-3β intervention by melatonin arrests the pathology and memory deficits in an Alzheimer's animal model.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Glycogen Synthase Kinase 3; Glycogen Synthase Ki | 2013 |
A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Circadian Rhythm; Cognition Disorders; Indoles; M | 2013 |
Melatonin for sundown syndrome and delirium in dementia: is it effective?
Topics: Aged, 80 and over; Alzheimer Disease; Central Nervous System Depressants; Delirium; Dose-Response Re | 2013 |
Effectiveness of melatonin for sundown syndrome and delirium.
Topics: Alzheimer Disease; Delirium; Humans; Male; Melatonin | 2014 |
Chronic exposure to aluminum and melatonin through the diet: neurobehavioral effects in a transgenic mouse model of Alzheimer disease.
Topics: Aluminum; Alzheimer Disease; Animals; Anti-Anxiety Agents; Citric Acid; Diet; Disease Models, Animal | 2014 |
Ergothioneine and melatonin attenuate oxidative stress and protect against learning and memory deficits in C57BL/6J mice treated with D-galactose.
Topics: Alzheimer Disease; Animals; Antioxidants; Brain; Chromatography, High Pressure Liquid; Disease Model | 2014 |
Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide as a neuroprotectant for Alzheimer's disease by hybridization of curcumin and melatonin.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain B | 2014 |
The melatonin-N,N-dibenzyl(N-methyl)amine hybrid ITH91/IQM157 affords neuroprotection in an in vitro Alzheimer's model via hemo-oxygenase-1 induction.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; C | 2015 |
Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF-K B/JNK signaling pathway in aging mouse model.
Topics: Aging; Alzheimer Disease; Animals; Antioxidants; Brain; Disease Models, Animal; Galactose; Inflammat | 2015 |
Beneficial effects of melatonin in a rat model of sporadic Alzheimer's disease.
Topics: Administration, Oral; Aging, Premature; Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, | 2015 |
Curcumin/melatonin hybrid 5-(4-hydroxy-phenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide ameliorates AD-like pathology in the APP/PS1 mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Blotting, Western; Brain; Coumarins; Dis | 2015 |
Melatonin attenuates impairments of structural hippocampal neuroplasticity in OXYS rats during active progression of Alzheimer's disease-like pathology.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Hippocampus; Male; Melato | 2015 |
Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Antioxidants; Cell Deat | 2016 |
Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPP(swe)/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anxiety; Disease | 2015 |
Melatonin Attenuates Memory Impairment, Amyloid-β Accumulation, and Neurodegeneration in a Rat Model of Sporadic Alzheimer's Disease.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anim | 2015 |
Moderate Changes in the Circadian System of Alzheimer's Disease Patients Detected in Their Home Environment.
Topics: Actigraphy; Aged; Aged, 80 and over; Alzheimer Disease; ARNTL Transcription Factors; Case-Control St | 2016 |
Plasma 8-isoPGF2α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Case-Control Studies; Cognitive Dysfunction; | 2015 |
Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogenic amine catabolism.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Astrocytes; Biogenic Amines; Brain; | 2008 |
The neuroprotective role of melatonin against amyloid beta peptide injected mice.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Calcium; Disease Models, An | 2008 |
Constant illumination induces Alzheimer-like damages with endoplasmic reticulum involvement and the protection of melatonin.
Topics: Alzheimer Disease; Animals; Antioxidants; Behavior, Animal; Cyclic AMP-Dependent Protein Kinases; Di | 2009 |
Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Antioxidants; B | 2009 |
Oxidative stress status and RNA expression in hippocampus of an animal model of Alzheimer's disease after chronic exposure to aluminum.
Topics: Aluminum Compounds; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Diet; Disease Models | 2010 |
Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Brain; Ca | 2009 |
A potential role for crystallization inhibitors in treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Calcium; Diphosphates; Durapatite; | 2010 |
Evaluation of the protective role of melatonin on the behavioral effects of aluminum in a mouse model of Alzheimer's disease.
Topics: Aluminum Compounds; Alzheimer Disease; Animals; Brain; Diet; Dose-Response Relationship, Drug; Femal | 2009 |
A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Animals; Animals, Newborn; Behavioral Sy | 2010 |
Differential effects of melatonin on amyloid-beta peptide 25-35-induced mitochondrial dysfunction in hippocampal neurons at different stages of culture.
Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cul | 2010 |
The role of environmental light in sleep and health: effects of ocular aging and cataract surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cataract Extraction; Child; Circadian | 2010 |
Choroid plexus portals and a deficiency of melatonin can explain the neuropathology of Alzheimer's disease.
Topics: Alzheimer Disease; Choroid Plexus; Humans; Melatonin; Models, Neurological; Oxidative Stress | 2010 |
Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3beta, tau and neuroinflammation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Astrocytes; Cell Death; Gly | 2010 |
Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A.
Topics: Alzheimer Disease; Animals; Antioxidants; Behavior, Animal; Disease Models, Animal; Male; Malondiald | 2011 |
Sleep in older adults with Alzheimer's disease.
Topics: Aged; Aging; Alzheimer Disease; Caregivers; Causality; Exercise; Family; Geriatric Assessment; Human | 2010 |
Study of the interaction between the amyloid beta peptide (1-40) and antioxidant compounds by nuclear magnetic resonance spectroscopy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Humans; Iridoid Glucosides; Iridoids; Melato | 2011 |
Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling.
Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Ani | 2011 |
Altered temporal patterns of anxiety in aged and amyloid precursor protein (APP) transgenic mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anxiety; Basal Nucleus of Meynert | 2011 |
Melatonin plus physical exercise are highly neuroprotective in the 3xTg-AD mouse.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Humans; Male; Melatonin; Mice; Mice, 129 Strain; | 2012 |
Circadian system functionality, hippocampal oxidative stress, and spatial memory in the APPswe/PS1dE9 transgenic model of Alzheimer disease: effects of melatonin or ramelteon.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Body Temperature; Circadian Rhythm; Dise | 2012 |
Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells.
Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antioxidants; Ca | 2012 |
Mitochondrial oxidative stress index, activity of redox-sensitive aconitase and effects of endogenous anti- and pro-oxidants on its activity in control, Alzheimer's disease and Swedish Familial Alzheimer's disease brain.
Topics: Aconitate Hydratase; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants | 2012 |
Melatonin decreases levels of S100β and NFΚB, increases levels of synaptophysin in a rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; CA3 Region, Hippocampal; Cell Count; Cerebral Cor | 2013 |
Marked improvement in delirium with ramelteon: five case reports.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Circadian Rhythm; Delirium; Female; Humans; Indenes; Mal | 2012 |
Relationship between amyloid beta protein and melatonin metabolite in a study of electric utility workers.
Topics: Adult; Alzheimer Disease; Amyloid beta-Peptides; Electromagnetic Fields; Environmental Monitoring; H | 2002 |
Comparison of melatonin versus vitamin C on oxidative stress and antioxidant enzyme activity in Alzheimer's disease induced by okadaic acid in neuroblastoma cells.
Topics: Alzheimer Disease; Animals; Ascorbic Acid; Catalase; Glutathione Transferase; Lipid Peroxidation; Me | 2002 |
[Effect of melatonin on learning and memory impairment induced by aluminum chloride and its mechanism].
Topics: Aluminum Chloride; Aluminum Compounds; Alzheimer Disease; Animals; Antioxidants; Cerebral Cortex; Ch | 2002 |
Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Chronobiology Disorders; Circadian Rhythm; Cricet | 2002 |
Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidosis; Animals; Dise | 2003 |
Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Female; Humans; Male; Melatonin; Plaque | 2003 |
Beta-amyloid modulates tyrosine kinase B receptor expression in SHSY5Y neuroblastoma cells: influence of the antioxidant melatonin.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blotting, Western; Brain-Derived Ne | 2003 |
Restless nights, listless days.
Topics: Adolescent; Adult; Aged; Aging; Alzheimer Disease; Biological Clocks; Circadian Rhythm; Darkness; Hu | 2003 |
Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Circadian Rhythm; Dopamine; Humans; Hydroxyindoleacet | 2003 |
Hypoxic remodelling of Ca2+ mobilization in type I cortical astrocytes: involvement of ROS and pro-amyloidogenic APP processing.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2004 |
Melatonin ameliorated okadaic-acid induced Alzheimer-like lesions.
Topics: Alzheimer Disease; Cell Survival; Humans; Melatonin; Microtubules; Mitochondria; Neuroblastoma; Neur | 2004 |
Melatonin attenuates isoproterenol-induced protein kinase A overactivation and tau hyperphosphorylation in rat brain.
Topics: Alzheimer Disease; Animals; Antioxidants; Brain; Cyclic AMP-Dependent Protein Kinases; Isoproterenol | 2004 |
Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chronobiology Disorders; Female; Humans; Male; Melatonin | 2004 |
Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Behavior, Animal; Brain; Choline O-Ace | 2004 |
Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats.
Topics: Alzheimer Disease; Animals; Apoptosis; Choline O-Acetyltransferase; Cognition Disorders; Disease Mod | 2004 |
Protective effect of melatonin on beta-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Astrocytes; Astrocytoma; Calcium; Cell | 2004 |
Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat.
Topics: Alzheimer Disease; Animals; Brain; Isoproterenol; Male; Melatonin; Neurofibrillary Tangles; Phosphor | 2005 |
Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Apoptosis Regulatory Pro | 2006 |
Genetically increased risk of sleep disruption in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Base Pairing; Case-Control S | 2006 |
Sleep in dementia assessment may require a multidisciplinary approach.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arousal; Combined Modality Therapy; Double-Blind Method; | 2006 |
Critical role of methionine-722 in the stimulation of human brain G-proteins and neurotoxicity induced by London familial Alzheimer's disease (FAD) mutated V717G-APP(714-723).
Topics: Aged; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Case-Control Studies; Cell Differe | 2007 |
[Melatonin in the elderly and Alzheimer's disease].
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antioxidants; Circadian Rhythm; Controlled Clinical Tri | 2006 |
Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5.
Topics: Alzheimer Disease; Animals; Cerebral Cortex; Cyclin-Dependent Kinase 5; Dopamine Antagonists; Enzyme | 2007 |
Analytical method for beta-amyloid fibrils using CE-laser induced fluorescence and its application to screening for inhibitors of beta-amyloid protein aggregation.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Benzothiazoles; Daunorubicin; Fluores | 2007 |
A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Biogenic Monoamines; DNA Mutational Analysis; Female; Gene Expression Regul | 2007 |
Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Central Nervous System Depressants; Cognition Disorders; | 2007 |
Effect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Melatonin; Mice; Neuroblastoma; | 2008 |
The oxidation products of melatonin derivatives exhibit acetylcholinesterase and butyrylcholinesterase inhibitory activity.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; M | 2008 |
REM sleep behaviour disorder treated with melatonin in a patient with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Diagnosis, Differential; Hormones; Humans; Male; Melatonin; Polysomnography | 2008 |
The mystery of Alzheimer's disease and its prevention by melatonin.
Topics: Alzheimer Disease; Cytochrome c Group; Free Radical Scavengers; Humans; Hydroxyl Radical; Melatonin; | 1995 |
Daily rhythm of serum melatonin in patients with dementia of the degenerate type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Circadian Rhythm; Dementia; Female; Humans; Male; Melato | 1996 |
Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Calcium; Ditiocarb; Doxo | 1997 |
Loss of intraventricular fluid melatonin can explain the neuropathology of Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Cerebral Ventricles; Humans; Melatonin; Models, Neurological | 1997 |
A new model for the pathophysiology of Alzheimer's disease. Aluminium toxicity is exacerbated by hydrogen peroxide and attenuated by an amyloid protein fragment and melatonin.
Topics: Aluminum; Alzheimer Disease; Amyloid; Blood Platelets; Free Radicals; Humans; Hydrogen Peroxide; In | 1997 |
Could exogenous melatonin prevent sudden infant death syndrome?
Topics: Alzheimer Disease; Animals; Humans; Infant; Injections, Intraventricular; Melatonin; Oxidative Stres | 1997 |
Inhibition of Alzheimer beta-fibrillogenesis by melatonin.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Circular Dichroism; Humans; Magnetic Resonance Spectroscop | 1998 |
Effects of melatonin in two individuals with Alzheimer's disease.
Topics: Affect; Aged; Alzheimer Disease; Circadian Rhythm; Cognition; Female; Humans; Melatonin; Motor Activ | 1998 |
Monozygotic twins with Alzheimer's disease treated with melatonin: Case report.
Topics: Aged; Alzheimer Disease; Antioxidants; Brain; Diseases in Twins; Humans; Magnetic Resonance Imaging; | 1998 |
Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Apolipoproteins E; Circadian Rhythm; Female; Geno | 1999 |
Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Case-Control Studies; Circadian Rhythm; Confounding F | 1999 |
Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Circadian Rhythm; Female; Humans; Light; Male; Melatonin | 1999 |
Alzheimer beta protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Base Sequence; Cell Line; DNA Damage; DNA Pr | 1999 |
N-acetylserotonin, melatonin and their derivatives improve cognition and protect against beta-amyloid-induced neurotoxicity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Avoidance Learning; Aziridines; Cells, Cultured; | 1999 |
Music therapy and melatonin.
Topics: Alzheimer Disease; Humans; Melatonin; Music Therapy | 2000 |
Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Circadian Rhy | 2000 |
Melatonin reduces interleukin secretion in amyloid-beta stressed mouse brain slices.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Brain; Culture Media, Conditioned; | 2001 |
Possible antioxidant mechanism in melatonin reversal of aging and chronic ethanol-induced amnesia in plus-maze and passive avoidance memory tasks.
Topics: Aging; Alzheimer Disease; Amnesia; Animals; Antioxidants; Avoidance Learning; Data Interpretation, S | 2001 |
Melatonin acts as antioxidant and pro-oxidant in an organotypic slice culture model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cerebral Cortex; Corpus Striatum; G | 2001 |
Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Arteries; Cerebrovascular Circulation; Hippocam | 2001 |
Alzheimer's disease: roles for mitochondrial damage, the hydroxyl radical, and cerebrospinal fluid deficiency of melatonin.
Topics: Alzheimer Disease; Humans; Hydroxyl Radical; Melatonin; Mitochondria; Oxidative Stress | 2001 |
Catecholamines inhibit lipid peroxidation in young, aged, and Alzheimer's disease brain.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adult; Aged; Aging; Alzheimer Disease; Autopsy; Brain; Catec | 2001 |
Actigraphic sleep-wake patterns and urinary 6-sulfatoxymelatonin excretion in patients with Alzheimer's disease.
Topics: Adult; Aged; Aging; Alzheimer Disease; Circadian Rhythm; Dementia; Female; Humans; Light; Male; Mela | 2001 |
Interaction of serotonin and melatonin with sodium, potassium, calcium, lithium and aluminium.
Topics: Aluminum; Alzheimer Disease; Animals; Brain; Calcium; Electrochemistry; Humans; In Vitro Techniques; | 2001 |
Disruption of pathologic amyloid beta-protein fibril assembly on the surface of cultured human cerebrovascular smooth muscle cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Cell Membrane; Cells, Cultured; Cerebral Amyloid An | 2001 |
Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cobalt; Glutathione; Humans; Melatonin; Neuroblas | 2001 |
Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoprotein E4; Apolipoproteins E; Astrocytes; | 2001 |
Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study.
Topics: Aged; Alzheimer Disease; Copper; Cross-Sectional Studies; Female; Humans; Iron; Male; Malondialdehyd | 2002 |
Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Female; Hippocampus; Humans; Immun | 2002 |
Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin.
Topics: Alzheimer Disease; Androstadienes; Animals; Antioxidants; Brain; Melatonin; Neurofibrillary Tangles; | 2002 |
Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease.
Topics: Adolescent; Adult; Aged; Aging; Alzheimer Disease; Circadian Rhythm; Female; Humans; Indoles; Male; | 1990 |
Dementia--the failure of hippocampal plasticity and dreams. Is there a preventative role for melatonin?
Topics: Alzheimer Disease; Hippocampus; Humans; Melatonin; Models, Biological; Sleep, REM | 1987 |